Details of the Drug

General Information of Drug (ID: DM4F29C)

Drug Name
Crizotinib
Synonyms Xalkori (TN); novel ALK inhibitors
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
L01ED01: Crizotinib
L01ED: Anaplastic lymphoma kinase (ALK) inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 450.3
Logarithm of the Partition Coefficient (xlogp) 3.7
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.75 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 42 hours [3]
Metabolism
The drug is metabolized via the CYP3A4 and CYP3A5 in which these enzymes mediates the O-dealkylation of the drug []
Unbound Fraction
The unbound fraction of drug in plasma is 0.09% [3]
Vd
The volume of distribution (Vd) of drug is 1772 L []
Chemical Identifiers
Formula
C21H22Cl2FN5O
IUPAC Name
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
Canonical SMILES
C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
InChI
InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
InChIKey
KTEIFNKAUNYNJU-GFCCVEGCSA-N
Cross-matching ID
PubChem CID
11626560
ChEBI ID
CHEBI:64310
CAS Number
877399-52-5
UNII
53AH36668S
DrugBank ID
DB08865
TTD ID
D03ZBT
VARIDT ID
DR00523
INTEDE ID
DR0387
ACDINA ID
D00154
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Modulator [4]
HGF/Met signaling pathway (HGF/Met pathway) TTKA5LP NOUNIPROTAC Inhibitor [5]
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Modulator [4]
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Modulator [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [6]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [6]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 3A5 (CYP3A5)
Main DME 		DEIBDNY CP3A5_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Gene/Protein Processing [9]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Post-Translational Modifications [9]
Acyl-CoA 6-desaturase (FADS2) OTUX531P FADS2_HUMAN Gene/Protein Processing [9]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [10]
ALK tyrosine kinase receptor (ALK) OTV3P4V8 ALK_HUMAN Drug Response [11]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [12]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Gene/Protein Processing [13]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [13]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Gene/Protein Processing [13]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Gene/Protein Processing [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proto-oncogene c-Met (MET) DTT MET 1.08E-03 -0.24 -0.4
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 9.69E-01 1.16E-03 3.56E-03
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 8.15E-01 6.20E-03 5.61E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 2.2889 5.7411 1.1716 16.3763
ES8 GDSC1; GDSC2 0.1064 1.5716 0.0958 24.2407
SK-ES-1 GDSC1; GDSC2; CTRP2; CCLE 0.6623 2.3181 0.6611 33.622
ES1 GDSC1; GDSC2 0.9276 2.6666 0.8543 23.5597
MHH-ES-1 GDSC2; CTRP2; CCLE 1.1428 3.5191 1.1198 30.6891
ES5 GDSC1; GDSC2 1.1619 3.3536 0.8874 15.3089
A-673 GDSC2; CTRP2; CCLE 1.2042 2.7381 1.2029 30.2374
EW-18 GDSC1; GDSC2 1.219 3.2824 1.0376 16.5426
EW-22 GDSC1; GDSC2 1.2374 3.4918 0.9985 16.6397
EW-7 GDSC2 1.3755 3.039 1.2678 15.069
EW-12 GDSC1; GDSC2 1.4823 2.8032 1.393 14.2636
TC71 CTRP2 1.4825 2.2994 1.4825 30.3921
EW-1 GDSC1; GDSC2 1.4886 3.6418 1.2255 14.8542
HuO9 GDSC2 1.5087 4.3808 0.9791 15.8386
SK-N-MC CTRP2 1.5346 2.3347 1.5346 30.0451
SK-PN-DW GDSC1; GDSC2 1.5847 4.1705 1.1418 14.8968
SaOS-2 GDSC2; CTRP2; CCLE 1.7816 3.9713 1.7543 26.7125
EW-11 GDSC1; GDSC2 1.8422 4.2872 1.3696 13.1024
ES7 GDSC1; GDSC2 1.9252 4.2579 1.4692 12.4108
CHSA8926 GDSC2 2.2882 7.6972 0.2226 17.0105
EW-24 GDSC1; GDSC2 2.2914 4.8484 1.5914 10.7803
NOS-1 [Human HNSCC] GDSC1; GDSC2 2.3618 4.3957 1.8658 9.3396
Hs 888.T CTRP2 2.413 4.6316 2.3591 24.3749
G-292 clone A141B1 GDSC2; CTRP2 2.4181 5.2291 2.2759 23.107
EW-3 GDSC1; GDSC2 2.4896 6.2121 1.1356 12.3432
U2OS GDSC2; CTRP2; CCLE 2.5344 4.1533 2.5219 21.9638
CHSA0108 GDSC2 2.5803 4.4895 1.8819 7.6359
MG-63 GDSC2; CTRP2; CCLE 2.5956 4.9715 2.51 21.815
CAL-72 GDSC2 2.6366 4.8441 1.9347 8.2513
EW-16 GDSC1; GDSC2 2.6374 6.2501 1.2544 11.4139
SJSA-1 GDSC1; GDSC2; CTRP2; CCLE 2.6621 4.4862 2.5729 17.3311
ES6 GDSC1; GDSC2 2.7443 5.7867 1.5803 9.6209
TC-71 GDSC1; GDSC2; CCLE 2.7559 4.5356 2.1968 6.7201
CHSA0011 GDSC2 2.9305 4.3688 2.2569 4.4632
SW1353 CTRP2; CCLE 2.9312 4.2079 2.9257 20.7588
Hs 822.T CTRP2 3.1602 4.0159 3.1597 19.2166
ES4 GDSC1; GDSC2 3.1669 8.5623 0.5714 13.315
HuO-3N1 GDSC2 3.356 6.5981 1.7122 7.5686
U-CH2 GDSC2 3.3925 6.1185 1.7546 6.1925
HOS GDSC2; CTRP2; CCLE 3.4958 5.704 3.3481 16.3977
H-EMC-SS GDSC1; GDSC2 3.5204 6.2834 2.0032 5.8424
CADO-ES1 GDSC2 3.548 7.3129 1.5116 8.1111
CAL-78 GDSC2; CTRP2; CCLE 3.6522 6.0384 3.4354 15.6533
EW-13 GDSC1; GDSC2 4.2575 7.3599 2.0194 4.4176
NY GDSC2 4.7685 9.9252 1.1343 7.5925
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 223 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 -3.576 0.615 -3.6004 63.4424
MEC1 CTRP2 1.9795 4.051 1.9546 27.1644
JM1 GDSC1; GDSC2; CTRP2 1.4456 2.4974 1.4455 30.6382
SR GDSC1; GDSC2; CTRP2 -3.0733 -1.2082 -3.0733 56.9506
DEL GDSC1; GDSC2; CTRP2; CCLE -2.6766 -1.0916 -2.6766 54.4737
Ki-JK CTRP2 -2.6132 -1.7109 -2.6132 57.6783
MOLM-6 CTRP2 -1.8781 0.4964 -1.8795 52.7752
SU-DHL-1 GDSC1; GDSC2; CTRP2 -1.863 -1.2957 -1.863 52.6801
KYO-1 CTRP2 -1.7443 -0.3294 -1.7443 51.8895
JURL-MK1 GDSC1; GDSC2; CTRP2 -1.6656 -0.1302 -1.6656 48.1593
Ku812 GDSC1; GDSC2; CTRP2; CCLE -1.6101 0.1702 -1.6102 47.8127
ALL-SIL GDSC1; GDSC2; CTRP2; CCLE -1.5043 0.0446 -1.5043 47.1517
NCO2 CTRP2; CCLE -1.4692 0.1001 -1.4693 50.0569
CTV-1 GDSC1; GDSC2 -1.3884 0.4085 -1.3936 35.4703
SUP-M2 GDSC1; GDSC2; CCLE -1.3655 -0.6095 -1.3655 35.2787
MOLM-16 GDSC2; CTRP2 -0.922 2.0983 -0.9392 46.4423
KHM-1B CTRP2; CCLE -0.7968 0.887 -0.797 45.5773
LAMA-84 GDSC1; GDSC2; CTRP2 -0.7239 0.5715 -0.7239 42.2769
SCC-3 GDSC1; GDSC2 -0.7183 1.6184 -0.7648 30.5831
CML-T1 GDSC2; CTRP2 -0.6567 1.3324 -0.6578 41.8604
MHH-CALL-2 GDSC2 -0.6114 1.0844 -0.6208 29.6381
EM-2 GDSC1; GDSC2; CTRP2; CCLE -0.58 1.1375 -0.5804 41.3794
Peer CTRP2 -0.5285 0.9119 -0.5286 43.79
SEM CTRP2 -0.4747 2.1587 -0.4851 43.4592
BV-173 GDSC1; GDSC2; CTRP2 -0.4324 1.4499 -0.4332 40.4586
BE-13 GDSC1; GDSC2 -0.4103 2.2076 -0.51 28.4696
AML-193 CTRP2 -0.3243 2.4798 -0.3415 42.4769
MEG-01 GDSC1; GDSC2; CCLE -0.2315 1.9939 -0.2905 26.9684
NALM-6 GDSC1; GDSC2; CTRP2 -0.2051 2.2285 -0.2129 39.0595
SET-2 CTRP2 -0.1908 2.3678 -0.2017 41.5721
Karpas-299 GDSC1; GDSC2; CTRP2; CCLE -0.1031 2.828 -0.1294 41.0319
Pfeiffer CTRP2; CCLE -0.0668 3.1829 -0.1136 40.8469
HuT 78 CTRP2; CCLE 0.0724 5.2725 -0.2797 40.6603
697 GDSC1; GDSC2; CCLE 0.1124 1.2665 0.11 24.1646
MOLM-13 GDSC1; GDSC2; CTRP2 0.1342 2.4256 0.127 36.9392
SUP-B8 GDSC2 0.1429 1.229 0.1398 26.0708
TALL-1 [Human adult T-ALL] GDSC2; CTRP2 0.2407 2.3525 0.2361 38.6801
SU-DHL-16 GDSC1; GDSC2 0.2676 1.4154 0.262 24.9449
KCL-22 GDSC1; GDSC2; CTRP2; CCLE 0.3101 2.0483 0.309 35.8215
RS4;11 GDSC1; GDSC2; CTRP2 0.3325 1.8344 0.3311 31.3978
MV4-11 GDSC1; GDSC2; CTRP2 0.3502 2.0071 0.3494 35.5705
IM-9 GDSC1; GDSC2 0.3664 2.1101 0.329 22.3864
NCI-H929 GDSC2; CTRP2 0.3884 2.4304 0.3841 35.3426
ATN-1 GDSC1; GDSC2 0.395 3.2123 0.1569 22.9631
KMS-21-BM CTRP2 0.4025 3.0517 0.3804 37.6577
EoL-1 GDSC1; GDSC2; CTRP2 0.4192 2.1596 0.4179 35.1406
GDM-1 GDSC1; GDSC2; CTRP2 0.4429 3.2113 0.4137 35.0787
K-562 GDSC1; GDSC2; CTRP2 0.4444 2.1322 0.4405 30.6605
SUP-B15 GDSC1; GDSC2; CTRP2 0.462 1.9808 0.4616 34.8709
F-36P CTRP2; CCLE 0.4681 2.4127 0.4649 37.1605
RPMI-8402 GDSC1; GDSC2; CTRP2; CCLE 0.4849 2.2103 0.4836 37.0425
Karpas-45 GDSC1; GDSC2 0.4856 2.4724 0.4103 21.6359
MHH-CALL-4 GDSC2; CTRP2 0.5398 3.1437 0.5172 36.7453
P12-Ichikawa GDSC2; CTRP2; CCLE 0.5532 1.309 0.5532 34.2995
A4/Fukuda GDSC1; GDSC2; CTRP2 0.5677 3.5964 0.4646 30.1713
MY-M12 GDSC1; GDSC2 0.6067 2.5004 0.5056 22.3008
ML-2 GDSC1; GDSC2 0.6234 2.1092 0.5989 20.4025
ALL-PO GDSC1; GDSC2 0.6354 2.4219 0.5777 20.4402
ST486 GDSC1; GDSC2; CTRP2 0.6637 3.0706 0.6477 33.659
KMS-28BM CTRP2 0.6691 3.7451 0.6101 36.0001
M-07e CTRP2 0.7494 3.0627 0.7357 35.3214
PL21 CTRP2 0.7541 2.5706 0.7513 35.2541
MOLT-4 GDSC1; GDSC2 0.7634 2.8098 0.651 19.6917
Kasumi-1 GDSC1; GDSC2; CTRP2 0.7742 2.0854 0.774 32.92
NB4 GDSC1; GDSC2; CTRP2 0.7948 1.8877 0.7948 34.9737
KMS-27 CTRP2 0.8593 4.2711 0.7529 34.8858
SKM-1 GDSC1; GDSC2; CTRP2 0.8723 2.3202 0.8718 32.3084
HPB-ALL CTRP2 0.875 2.6201 0.8726 34.447
MOLT-16 GDSC1; GDSC2; CTRP2; CCLE 0.8878 2.4208 0.8869 32.2124
BC-1 GDSC1; GDSC2 0.8958 3.4014 0.6521 19.2245
KMS-26 CTRP2; CCLE 0.9036 2.7021 0.9005 34.2591
HAL-01 GDSC1; GDSC2 0.9039 1.9563 0.8977 18.2219
Farage GDSC1; GDSC2 0.9272 2.6276 0.8277 16.3837
MOLT-13 GDSC2; CTRP2 0.9385 3.4385 0.9132 31.9722
CRO-AP2 GDSC2 0.9489 3.9601 0.4418 21.2124
SU-DHL-5 GDSC2 0.9736 2.2667 0.9522 17.7551
Kasumi-2 CTRP2; CCLE 0.9881 2.9884 0.9811 33.7089
OCI-AML-5 GDSC1; GDSC2; CTRP2; CCLE 1.0106 2.3205 1.0104 31.4433
KO52 CTRP2; CCLE 1.0118 3.7972 0.9648 33.6825
GR-ST GDSC1; GDSC2 1.0152 3.5411 0.7415 18.4514
HuNS1 CTRP2 1.022 4.6335 0.7596 29.6574
MM1.S GDSC2; CTRP2 1.0235 2.6534 1.0218 31.3675
Ri-1 CTRP2 1.0319 4.812 0.8546 33.9655
RCH-ACV GDSC2; CTRP2 1.0346 2.8796 1.0303 33.3901
KE-37 GDSC1; GDSC2; CTRP2 1.058 2.617 1.0567 31.1507
H9 GDSC1; GDSC2 1.0587 2.0747 1.0519 17.0592
P32/ISH GDSC1; GDSC2 1.0592 2.1826 1.0471 17.0753
PF-382 GDSC1; GDSC2; CTRP2 1.0974 2.8786 1.0938 30.9116
OCI-M1 GDSC1; GDSC2; CTRP2 1.1121 2.1918 1.112 30.8091
Hs 611.T CTRP2 1.1539 2.9113 1.1504 32.5929
MOLP-8 GDSC1; GDSC2; CTRP2; CCLE 1.1723 3.6491 1.1428 30.5252
KMS-34 CTRP2; CCLE 1.1813 2.639 1.1804 32.4015
SUP-T1 GDSC1; GDSC2; CTRP2; CCLE 1.1863 3.2417 1.1759 30.3778
L-363 GDSC1; GDSC2; CTRP2; CCLE 1.1958 4.0879 1.1312 30.4883
Mono-Mac-1 CTRP2; CCLE 1.2093 3.5903 1.1846 32.2943
KY821 GDSC1; GDSC2 1.2278 3.3155 1.0383 16.509
JVM-3 GDSC1; GDSC2; CTRP2; CCLE 1.2576 2.9998 1.2539 29.9114
SU-DHL-6 GDSC1; GDSC2; CTRP2; CCLE 1.2672 3.004 1.2634 29.8518
BL-41 GDSC1; GDSC2; CCLE 1.2714 2.5642 1.2364 15.5665
KOPN-8 GDSC1; GDSC2 1.2746 2.3811 1.2576 15.4732
L-1236 GDSC1; GDSC2 1.2902 3.934 0.9117 16.8261
Namalwa GDSC1; GDSC2 1.2961 2.9063 1.2091 15.5842
OCI-Ly7 GDSC2 1.3027 3.5642 0.9679 17.1286
SU-DHL-10 GDSC2; CTRP2; CCLE 1.3208 2.6713 1.3203 29.5066
P30/OHK GDSC1; GDSC2 1.329 2.6481 1.287 15.16
KMS-11 GDSC2; CTRP2; CCLE 1.3598 3.1509 1.3546 31.2265
CMK-86 CCLE 1.3854 3.8606 0.946 15.9349
SIG-M5 GDSC1; GDSC2; CTRP2; CCLE 1.3938 2.0507 1.3938 30.983
VAL GDSC1; GDSC2 1.3985 3.8567 1.0558 15.8639
P31/FUJ GDSC1; GDSC2; CTRP2; CCLE 1.4033 3.8641 1.3683 31.0366
GA-10 GDSC1; GDSC2; CTRP2 1.4037 2.825 1.4027 28.9906
CCRF-CEM GDSC1; GDSC2 1.4228 3.6094 1.1643 15.3288
OCI-Ly19 GDSC1; GDSC2; CTRP2 1.4404 3.1306 1.4365 30.6853
NKM-1 GDSC1; GDSC2 1.4411 4.1642 0.9906 20.588
DoHH2 GDSC1; GDSC2; CCLE 1.4442 2.283 1.4314 12.05
SUP-T11 CTRP2 1.4599 4.6725 1.338 30.9496
SU-DHL-8 GDSC1; GDSC2; CTRP2; CCLE 1.499 3.709 1.4773 28.4598
Reh GDSC1; GDSC2; CTRP2; CCLE 1.5009 3.0183 1.499 28.3861
KMS-12-BM GDSC1; GDSC2; CTRP2; CCLE 1.5085 3.9894 1.4686 28.4579
NU-DUL-1 GDSC1; GDSC2; CTRP2 1.5334 3.5187 1.5212 30.0934
LP-1 GDSC1; GDSC2; CTRP2; CCLE 1.547 2.9192 1.5461 28.0949
CMK CTRP2 1.5526 2.0477 1.5526 29.9249
OCI-AML-2 GDSC1; GDSC2; CTRP2; CCLE 1.5629 2.5784 1.5628 27.9933
OCI-AML-3 GDSC1; GDSC2; CTRP2 1.5883 3.7334 1.5682 27.8974
TF-1 CTRP2 1.6111 2.3037 1.6111 24.5056
BONNA-12 GDSC2 1.6164 3.2827 1.4043 13.6529
JVM-2 GDSC1; GDSC2 1.6232 3.6095 1.3823 13.7518
AMO1 GDSC1; GDSC2; CTRP2; CCLE 1.6313 3.2602 1.6275 27.5776
Daudi GDSC1; GDSC2; CTRP2 1.6729 3.1081 1.6713 27.3106
WSU-NHL GDSC1; GDSC2 1.6893 2.767 1.6553 12.4176
OPM-2 GDSC1; GDSC2; CTRP2; CCLE 1.717 3.3673 1.7123 27.0451
KE-97 CTRP2; CCLE 1.7214 3.9096 1.6958 28.8861
KMS-20 CTRP2 1.7336 3.7652 1.7163 28.7771
Karpas-1106P GDSC2 1.7363 3.3224 1.5913 12.5066
Mono-Mac-6 GDSC1; GDSC2; CTRP2 1.7375 5.4838 1.4845 29.5461
A3/Kawakami GDSC1; GDSC2 1.7421 4.0821 1.3437 13.5286
RPMI-8866 GDSC1; GDSC2 1.7498 4.1968 1.3076 13.6602
CTB-1 GDSC1; GDSC2 1.7623 3.8659 1.3433 13.4054
NK-92MI GDSC1; GDSC2 1.7692 3.1302 1.6191 11.9505
MC116 GDSC1; GDSC2; CTRP2; CCLE 1.7838 2.2772 1.7838 28.3848
SUP-HD1 GDSC1; GDSC2; CTRP2 1.814 4.784 1.7007 26.7842
Mino CTRP2; CCLE 1.8149 2.7223 1.8149 28.1775
PL-21 GDSC1; GDSC2 1.85 3.91 1.4173 12.6863
DND-41 GDSC1; GDSC2; CTRP2 1.8673 3.554 1.8607 26.1119
MOTN-1 CTRP2 1.8886 3.507 1.8834 27.7037
BC-3 GDSC1; GDSC2 1.924 3.3766 1.705 10.894
Ramos.2G6.4C10 GDSC1; GDSC2 1.9315 5.1777 1.0793 14.1241
KMS-18 CTRP2 1.941 3.5359 1.9359 27.3542
HEL GDSC1; GDSC2; CTRP2 1.9438 3.1839 1.943 25.616
BALL-1 GDSC1; GDSC2 1.947 4.1932 1.5182 12.1292
JSC-1 GDSC1; GDSC2 1.9864 4.3989 1.4755 12.1954
Karpas-422 GDSC1; GDSC2; CTRP2; CCLE 1.9904 3.5068 1.9865 25.3348
QIMR-WIL GDSC1; GDSC2 2.0049 3.7639 1.6402 10.926
RPMI-6666 GDSC1; GDSC2; CTRP2 2.009 4.2741 1.9687 25.3335
L-540 GDSC1; GDSC2; CTRP2 2.0237 4.1238 1.9956 25.2031
NU-DHL-1 CTRP2 2.0352 3.6066 2.03 26.7271
Jurkat GDSC2; CTRP2; CCLE 2.0457 4.9811 1.9181 25.3841
HC-1 GDSC1; GDSC2 2.0519 4.3697 1.5561 11.6415
SU-DHL-4 GDSC1; GDSC2; CTRP2; CCLE 2.0746 3.8391 2.0632 26.4856
Loucy GDSC1; GDSC2 2.0769 4.9808 1.3151 12.6436
NOMO-1 GDSC1; GDSC2; CTRP2 2.0969 3.9324 2.0822 24.7035
DB GDSC1; GDSC2; CTRP2 2.185 3.8964 2.1741 24.141
RL GDSC1; GDSC2; CTRP2 2.1912 3.1424 2.1911 25.6709
JeKo-1 GDSC2; CTRP2 2.1915 4.6982 2.1162 25.9231
U-698-M GDSC1; GDSC2 2.1995 4.1154 1.8162 10.0476
DG-75 GDSC1; GDSC2 2.2092 4.7354 1.5594 11.1609
Karpas-620 GDSC1; GDSC2; CTRP2; CCLE 2.2243 5.6257 1.9818 24.6449
MHH-PREB-1 GDSC1; GDSC2 2.2354 3.7286 2.0047 9.1187
RPMI-8226 GDSC1; GDSC2; CTRP2 2.2543 4.6068 2.1939 23.8655
MJ CCLE 2.26 3.9536 1.8218 8.5011
MHH-CALL-3 CTRP2 2.2905 7.4567 1.4907 27.7688
CESS GDSC1; GDSC2 2.2933 4.5713 1.7181 10.2027
LC4-1 GDSC1; GDSC2 2.2992 5.0483 1.5073 11.1404
WSU-DLCL2 GDSC1; GDSC2; CTRP2 2.3194 4.5033 2.2736 24.9708
EB1 CTRP2; CCLE 2.3475 5.0422 2.2327 25.02
KM-H2 GDSC1; GDSC2; CTRP2 2.3939 4.9838 2.2919 23.1272
ME1 CTRP2 2.4289 6.2464 2.0418 25.4316
EHEB GDSC1; CTRP2 2.4582 4.78 2.3895 24.1243
HT GDSC1; GDSC2; CTRP2; CCLE 2.4706 3.9814 2.4631 23.8343
JJN-3 GDSC1; GDSC2; CTRP2 2.4793 4.2781 2.4586 22.3337
U-937 CTRP2; CCLE 2.5152 5.1489 2.3952 23.9209
Granta-519 GDSC1; GDSC2; CTRP2; CCLE 2.5448 4.4053 2.5181 21.9438
BL-70 CTRP2; CCLE 2.6168 3.0512 2.6168 22.8351
L-428 GDSC1; GDSC2; CTRP2; CCLE 2.6632 4.5131 2.6334 21.2139
VL51 GDSC1; GDSC2 2.672 4.784 1.9976 7.8658
MEC-1 CCLE 2.6939 5.2327 1.6193 8.2793
HD-MY-Z CTRP2; CCLE 2.7117 4.0157 2.7074 22.217
MOLP-2 CTRP2 2.7382 6.8846 2.1763 24.0116
EJM GDSC1; GDSC2; CTRP2 2.8134 4.6221 2.7815 20.2824
ARH-77 GDSC1; GDSC2 2.8299 4.5329 2.2698 6.1837
U266B1 GDSC1; GDSC2; CTRP2 2.8451 4.6519 2.8122 20.0877
Jiyoye GDSC1; GDSC2 2.8835 5.4544 1.8714 7.9074
THP-1 GDSC1; GDSC2; CTRP2 2.9001 4.866 2.8483 21.1229
WIL2 NS GDSC1; GDSC2 2.9205 4.9439 2.1561 6.4783
HL-60 GDSC1; GDSC2; CTRP2 2.9262 4.4344 2.9118 19.5226
HDLM-2 GDSC1; GDSC2; CTRP2 2.9305 5.7744 2.7159 20.1481
CA46 GDSC1; GDSC2 2.9415 5.5312 1.8862 7.6952
EB2 GDSC1; GDSC2; CCLE 2.9936 5.9983 1.7012 8.4423
RC-K8 GDSC2 3.0003 6.1937 1.6099 8.8578
KMOE-2 GDSC1; GDSC2 3.0283 5.6487 1.9056 7.3939
Ci-1 CTRP2; CCLE 3.0331 4.1677 3.0301 20.0716
TK [Human B-cell lymphoma] GDSC2 3.052 4.7274 2.3832 5.0833
SK-MM-2 GDSC1; GDSC2; CTRP2; CCLE 3.1768 5.5276 3.0393 18.355
TUR GDSC1; GDSC2 3.2572 6.2443 1.8065 7.3379
KG-1 GDSC1; GDSC2; CCLE 3.3591 6.0537 1.9869 6.2587
MLMA GDSC1; GDSC2 3.3627 8.0022 1.0157 10.8337
Raji GDSC1; GDSC2; CTRP2; CCLE 3.4288 4.8526 3.4063 16.409
YT GDSC1; GDSC2 3.4676 5.2744 2.4643 4.8478
MN-60 GDSC1; GDSC2 3.4863 5.4302 2.4014 4.0257
ROS-50 GDSC1; GDSC2 3.5031 5.9776 1.9068 5.0788
P3HR-1 CTRP2; CCLE 3.5142 7.5078 2.7808 19.5318
OCI-Ly3 CTRP2 3.6041 5.6083 3.4863 16.6627
Toledo CCLE 3.8675 7.0488 1.6451 5.4415
Hs 445 GDSC1; GDSC2 3.8736 6.1059 2.3587 3.5021
HEL 92.1.7 CTRP2; CCLE 3.9104 5.3964 3.6955 8.9217
OCI-Ly10 CTRP2; CCLE 4.0617 6.0059 3.8911 13.8047
HH [Human lymphoma] GDSC1; GDSC2; CCLE 4.1085 5.8588 2.6337 1.8985
KMM-1 CTRP2; CCLE 4.1164 7.4852 3.4261 15.3987
REC-1 CTRP2 4.4534 5.583 4.4089 10.7508
Karpas-231 GDSC1; GDSC2 4.4835 6.1226 2.7301 1.0736
BDCM CCLE 4.9445 6.6532 2.4297 0.5267
ME1 GDSC1; GDSC2 4.9524 8.308 2.0211 3.3959
JM-1 CCLE 5.6387 7.1558 2.5139 0.1284
⏷ Show the Full List of 223 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 1.6681 5.0947 1.3459 25.2958
TE15 CTRP2 3.7397 6.5344 3.3801 16.636
OE33 GDSC2; CTRP2; CCLE 2.3697 6.5607 1.882 24.5551
OE21 GDSC2; CTRP2; CCLE 2.4269 4.1344 2.3751 17.6143
TE-11 GDSC1; GDSC2; CTRP2; CCLE 2.4514 4.3185 2.3747 18.7879
TE-10 GDSC1; GDSC2; CTRP2 2.5746 4.8641 2.5025 23.3606
T.T GDSC2 2.582 4.7404 1.9302 10.8765
KYSE-150 GDSC2; CTRP2; CCLE 2.7799 4.7264 2.7365 21.8948
KYSE-140 GDSC2; CTRP2; CCLE 2.8542 5.1466 2.7605 20.2262
TE-8 GDSC1; GDSC2 2.8708 5.3258 1.923 7.6965
KYSE-410 GDSC2; CTRP2; CCLE 3.0088 5.1742 2.9222 19.2377
TE-6 GDSC1; GDSC2; CTRP2 3.0172 5.4588 2.7064 14.6137
EC-GI-10 GDSC1; GDSC2; CTRP2 3.0299 5.6321 2.6614 14.7439
OE19 GDSC2; CTRP2 3.0874 5.0505 2.907 13.6696
KYSE-180 GDSC2; CTRP2; CCLE 3.101 5.3121 2.9984 18.714
TE-9 GDSC1; GDSC2; CTRP2; CCLE 3.1118 4.5039 3.0995 18.3565
KYSE-520 GDSC2; CTRP2; CCLE 3.166 5.4188 2.8812 13.5291
KYSE-30 CTRP2; CCLE 3.1751 4.4348 3.1675 19.141
KYSE-70 GDSC2; CTRP2; CCLE 3.1988 5.901 2.9769 18.4988
TE-1 GDSC1; GDSC2; CTRP2; CCLE 3.267 4.929 3.2295 17.4669
TE-4 GDSC2; CTRP2 3.4363 4.7506 3.4212 16.3383
COLO 680N GDSC2; CTRP2 3.5652 5.5935 3.4472 15.8661
TE-5 GDSC1; GDSC2; CTRP2; CCLE 3.5896 4.5186 3.5871 15.3414
KYSE-510 GDSC2; CTRP2; CCLE 3.627 4.622 3.6227 16.1194
TE-15 GDSC1; GDSC2; CCLE 3.6416 6.5793 1.9514 5.8433
KYSE-450 GDSC2; CTRP2; CCLE 3.6807 5.3654 3.4575 9.883
TE-14 CTRP2 3.7798 5.4564 3.7052 15.3417
KYSE-270 GDSC2 3.8278 6.4084 2.1773 4.4269
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 4.1504 5.6588 3.8523 7.5593
KP-4 GDSC2; CTRP2; CCLE 1.0138 4.6301 0.8658 31.8825
SNU-213 CTRP2 1.5756 4.2231 1.518 29.9647
TCC-Pan2 CTRP2 1.831 4.1937 1.7891 28.2107
MIA PaCa-2 GDSC2; CTRP2; CCLE 1.9806 3.3459 1.9788 25.3893
PaTu 8988s CTRP2 2.0466 5.0682 1.904 27.1181
QGP-1 GDSC2; CTRP2; CCLE 2.1223 4.5845 2.0566 24.7068
Panc 05.04 CTRP2 2.2265 6.7533 1.6647 27.3743
HuP-T4 GDSC2; CTRP2; CCLE 2.339 4.4592 2.2984 23.2734
PK-59 CTRP2; CCLE 2.4297 4.7605 2.3616 24.312
HPAC GDSC2; CTRP2; CCLE 2.4516 5.4638 2.2654 23.042
Panc 08.13 GDSC2; CTRP2 2.5323 4.5315 2.4947 22.0563
Capan-2 GDSC2; CTRP2; CCLE 2.6248 4.9758 2.5406 21.6281
BxPC-3 GDSC2; CTRP2; CCLE 2.6531 4.4028 2.6309 21.253
KCI-MOH1 CCLE 2.795 4.8077 1.9201 6.3821
Panc 02.03 GDSC2; CTRP2; CCLE 2.8159 4.94 2.7497 20.3765
YAPC GDSC2; CTRP2 2.8647 5.9435 2.6014 20.7214
KP-1NL CCLE 2.8739 4.6569 2.0643 5.3929
PK-45H CTRP2; CCLE 3.005 5.6278 2.636 15.9745
DAN-G GDSC2; CTRP2 3.024 5.2994 2.9176 19.207
CFPAC-1 GDSC2; CTRP2 3.0309 4.2331 3.0265 18.8368
PaTu 8902 GDSC2; CTRP2; CCLE 3.0346 4.1496 3.0319 18.8088
KP-3 GDSC2; CTRP2; CCLE 3.1222 4.7383 3.095 18.3386
KP-1N GDSC2; CCLE 3.1503 5.079 2.2966 5.2564
Panc 10.05 GDSC2; CTRP2; CCLE 3.1968 4.6211 3.181 17.8368
PL45 CCLE 3.2056 4.7182 2.3057 3.2808
Panc 03.27 GDSC2; CTRP2; CCLE 3.2634 4.7377 3.2425 18.5975
SNU-410 CTRP2 3.2957 6.3391 2.9593 19.4996
Panc 04.03 GDSC2; CTRP2; CCLE 3.3224 5.2463 3.2475 18.3894
PSN1 GDSC1; GDSC2; CTRP2; CCLE 3.3762 5.3635 3.2862 16.9547
L3.3 CTRP2; CCLE 3.3886 5.2459 3.3185 17.9318
Hs 766T GDSC2; CTRP2; CCLE 3.4015 4.1789 3.4011 17.6088
PaTu 8988t GDSC2; CTRP2 3.4288 4.2749 3.428 16.3404
KP-2 GDSC2; CTRP2; CCLE 3.4491 5.183 3.3923 16.3915
HuP-T3 GDSC2; CTRP2; CCLE 3.5153 5.3278 3.2904 10.9876
PK-1 CCLE 3.5978 5.4663 2.2224 2.9375
HPAF-II GDSC2; CTRP2; CCLE 3.6398 5.7875 3.4856 15.5203
Capan-1 GDSC2 3.7489 6.1294 2.2562 4.2023
SUIT-2 GDSC2; CTRP2; CCLE 3.7647 5.518 3.6779 14.5184
SU.86.86 GDSC2; CTRP2; CCLE 3.7772 5.7225 3.65 14.5734
MZ-PC-1 GDSC1; GDSC2 3.811 7.3366 1.4648 6.8983
AsPC-1 GDSC2; CTRP2; CCLE 3.8429 5.9473 3.6676 14.3239
SW1990 GDSC2; CTRP2; CCLE 3.8487 4.7293 3.8453 14.6393
PL4 GDSC2 4.1055 8.3467 1.4289 7.4081
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 80 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 1.1132 2.6778 1.1118 32.8573
COLO 792 GDSC2; CTRP2 1.6515 3.2271 1.6484 27.4489
IGR-1 GDSC2; CTRP2 1.7573 2.9593 1.7569 26.7799
WM88 CTRP2; CCLE 1.8959 3.1643 1.895 27.6408
CP50-MEL-B GDSC2 1.979 4.1597 1.4437 12.0771
Hs 294T CTRP2; CCLE 1.9916 3.3666 1.9896 27.007
Hs 852.T CTRP2; CCLE 2.0511 3.9663 2.0334 26.6631
A-431 GDSC2 2.1193 3.8556 1.7206 10.0767
CP67-MEL GDSC1 2.1553 7.5648 -1.3765 14.2125
Hs 688(A).T CTRP2 2.1605 4.5699 2.0987 26.0835
WM266-4 CTRP2; CCLE 2.1844 3.6431 2.1805 25.7289
SK-MEL-24 GDSC2; CCLE 2.1896 4.064 1.8266 10.0322
VMRC-MELG GDSC2 2.2055 4.0739 1.7125 9.8148
COLO 829 GDSC1; GDSC2; CTRP2 2.2133 5.4099 2.018 24.5584
MZ-MEL-7 GDSC1; GDSC2 2.239 3.3701 2.0456 7.9048
HT-144 GDSC1; GDSC2; CTRP2; CCLE 2.2571 3.4188 2.2563 23.659
HMV-II GDSC2 2.3082 4.3838 1.8159 9.7208
RPMI-7951 GDSC2; CCLE 2.3116 4.8769 1.5985 10.6909
Mel Ho GDSC2; CTRP2; CCLE 2.3566 2.9722 2.3566 24.5689
K029AX CTRP2; CCLE 2.3583 3.3774 2.3554 19.1828
Hs 934.T CTRP2 2.428 5.3337 2.2666 24.6452
UACC-257 GDSC1; GDSC2; CTRP2; CCLE 2.4408 3.1911 2.4408 22.5092
MDA-MB-435S CTRP2; CCLE 2.4487 4.8123 2.3752 24.2036
SK-MEL-3 GDSC2; CTRP2 2.4715 3.372 2.4714 23.8036
A101D GDSC1; GDSC2; CTRP2 2.4762 3.9187 2.4705 22.3057
M14 GDSC2 2.484 4.5303 1.7714 7.2413
LOX-IMVI GDSC1; GDSC2; CTRP2; CCLE 2.5134 4.1455 2.5007 22.0958
CJM [Human melanoma] CTRP2 2.5217 3.1847 2.5217 23.4689
A-388 GDSC1; GDSC2 2.5323 5.3991 1.3915 10.5663
G-361 GDSC2; CTRP2; CCLE 2.5714 3.5261 2.5711 21.6945
WM983B CTRP2; CCLE 2.5823 5.0276 2.4873 23.3879
WM1552C GDSC2 2.6054 4.5332 2.0498 7.809
Hs 895.T CTRP2; CCLE 2.6593 4.3731 2.6393 22.619
MZ-MEL-2 GDSC1; GDSC2 2.6911 4.5043 1.9772 6.7558
COLO 800 GDSC1; GDSC2; CTRP2 2.6974 4.2294 2.6508 16.9211
A-375 GDSC2; CTRP2; CCLE 2.7063 4.5771 2.6732 20.9549
SK-MEL-1 GDSC1; GDSC2; CTRP2 2.7192 3.6012 2.719 22.1538
Mel JuSo GDSC2; CTRP2 2.7361 4.4668 2.7128 20.7379
Hs 944.T CTRP2; CCLE 2.7599 4.9108 2.6938 22.1057
Hs 940.T GDSC2; CTRP2 2.8214 3.6205 2.8213 21.4722
GAK GDSC1; GDSC2 2.8363 4.1379 2.462 5.2821
A2058 GDSC2; CTRP2; CCLE 2.8754 3.8398 2.8748 19.7965
IGR-39 CTRP2; CCLE 2.9159 4.7364 2.8788 20.9675
SH-4 GDSC1; GDSC2 2.9215 5.3429 1.961 7.3922
SK-MEL-28 GDSC2; CTRP2 2.9671 3.8493 2.9667 20.5029
DJM-1 GDSC1; GDSC2 3.0417 4.9019 2.0836 5.1641
Hs 938.T GDSC2; CCLE 3.0904 4.5583 2.2948 3.6019
COLO 783 GDSC2 3.1001 5.0705 2.0469 5.2252
Malme-3M CTRP2; CCLE 3.108 5.3937 2.9911 19.9632
G-mel GDSC2 3.1307 4.81 2.2015 3.6036
IGR-37 GDSC2; CTRP2; CCLE 3.1396 4.0494 3.1388 18.1467
SK-MEL-30 GDSC2; CTRP2; CCLE 3.1506 4.3648 3.1448 19.2982
IST-MEL1 GDSC1; GDSC2 3.1536 4.9941 2.3417 6.4817
IPC-298 GDSC2; CTRP2; CCLE 3.1632 4.4914 3.153 19.2289
WM793 GDSC2; CTRP2; CCLE 3.1841 5.0949 3.1216 18.0651
WM278 GDSC2 3.1994 5.8021 1.9783 6.6524
MeWo GDSC2; CTRP2; CCLE 3.2195 5.4629 3.0986 19.2343
WM1799 CTRP2; CCLE 3.2301 4.7707 3.2052 18.8329
SK-MEL-5 GDSC2; CTRP2; CCLE 3.2661 3.9776 3.266 17.3544
SF8657 CCLE 3.2878 4.7903 2.3319 2.9637
LB2518-MEL GDSC1; GDSC2 3.3032 5.2355 2.1238 4.2951
SK-MEL-31 GDSC2; CTRP2; CCLE 3.3449 5.0828 3.2944 18.1555
COLO 679 GDSC2; CCLE 3.3654 4.8626 2.5875 3.3937
WM115 GDSC2; CTRP2; CCLE 3.3837 5.1968 3.3205 16.8207
RVH-421 GDSC2; CTRP2; CCLE 3.6081 4.1591 3.6081 16.2308
UACC-62 GDSC2; CTRP2; CCLE 3.6192 5.3808 3.5449 15.3857
Hs 695T CCLE 3.6889 6.4526 1.8087 4.9289
WT2-iPS GDSC2; CTRP2; CCLE 3.7321 5.2064 3.6906 14.5749
CP66-MEL GDSC1; GDSC2 3.917 5.4927 2.4095 1.3585
Hs 936.T CTRP2; CCLE 3.9645 7.5537 3.2382 16.5386
WM35 GDSC2 4.0064 7.6481 1.6994 8.1607
SK-MEL-2 GDSC1; GDSC2; CTRP2; CCLE 4.0208 4.6656 4.0202 12.6416
LB373-MEL-D GDSC1; GDSC2 4.0448 6.5794 1.988 3.5715
451Lu GDSC2 4.0717 5.8188 2.3517 1.675
CHL-1 GDSC2; CCLE 4.1417 7.4033 1.9175 5.0788
Hs 839.T CTRP2 4.2189 5.7209 4.1302 12.4668
HMCB CTRP2; CCLE 4.5502 5.0836 4.5491 9.9582
MMAc-SF GDSC1; GDSC2 4.5991 6.1466 2.4763 0.6313
COLO 741 CCLE 4.6464 7.5847 1.8909 2.9413
EquiPSC Line K2 GDSC2 4.1487 7.4187 1.659 5.1525
⏷ Show the Full List of 80 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ESO-51 GDSC2 -3.4149 -0.9209 -3.4208 50.6982
KYSE-220 GDSC2 1.6841 3.8434 1.3691 13.6063
OACP4 C GDSC2 1.7058 3.5255 1.4987 12.9914
OACM5.1 C GDSC2 2.1228 4.5006 1.574 11.349
FLO-1 GDSC2 2.1608 4.5779 1.5797 11.2108
TE-12 GDSC1; GDSC2 2.2964 5.104 1.3164 9.9129
KYSE-50 GDSC2 2.8191 4.5963 2.229 6.4012
HCE-4 GDSC1; GDSC2 3.2899 8.1404 0.6672 12.5539
SK-GT-4 GDSC2 3.3412 6.1527 1.9226 6.6024
ESO-26 GDSC2 4.0523 7.0372 2.0322 4.7032
KYAE-1 GDSC2 5.6561 7.2504 2.8046 0.2146
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2; CTRP2 3.4245 5.4284 3.3268 16.6782
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NB1 GDSC1; GDSC2; CTRP2 -1.3956 1.9285 -1.4175 49.5721
NH-6 CTRP2 -0.1866 3.3304 -0.3041 37.7171
SJNB-14 GDSC1; GDSC2 0.1341 2.4954 0.0288 24.3974
KP-N-SI9s CTRP2; CCLE 0.7076 3.4888 0.6708 35.6737
Kelly GDSC1; GDSC2; CTRP2; CCLE 0.8327 2.851 0.8264 32.5735
MHH-NB-11 GDSC1; GDSC2; CTRP2 0.9144 2.5963 0.9125 34.1831
NB(TU)1 GDSC1; GDSC2 1.0264 3.041 0.8348 16.0002
KP-N-YS GDSC1; GDSC2 1.0899 2.4901 1.0292 17.7032
IMR-5 GDSC1; GDSC2 1.102 2.2361 1.0882 16.7597
SK-N-SH GDSC2; CTRP2; CCLE 1.1581 3.4811 1.1375 32.6216
GOTO GDSC1; GDSC2 1.2678 4.0195 0.8573 17.1292
NB69 GDSC1; GDSC2 1.2789 3.3839 1.075 16.1842
CHP-212 GDSC2; CCLE 1.2917 3.6831 0.9981 16.4589
TGW GDSC1; GDSC2 1.3573 3.0804 1.2387 15.2493
NH-12 GDSC1; GDSC2 1.3615 3.9549 0.9814 16.2989
CHP-134 GDSC2 1.3766 2.7315 1.2937 12.8519
SK-N-DZ GDSC1; GDSC2; CTRP2; CCLE 1.4658 3.4177 1.4556 28.631
IMR-32 CTRP2; CCLE 1.5078 3.2014 1.4923 25.2985
SJNB-10 GDSC1; GDSC2 1.5104 3.5999 1.2626 14.6268
CHP-126 GDSC1; GDSC2; CTRP2 1.5448 3.9197 1.5117 30.0877
SJNB-12 GDSC2 1.7076 4.2912 1.2255 18.2675
SK-N-MC-IXC GDSC2 1.7422 3.551 1.4455 12.945
SiMa GDSC1; GDSC2; CTRP2; CCLE 1.8391 3.4407 1.8345 26.2821
SJNB-13 GDSC1; GDSC2 1.8835 3.6163 1.6628 11.7143
SJNB-17 GDSC1; GDSC2 1.995 3.4827 1.7419 10.4267
LA-N-6 GDSC1; GDSC2 2.2366 4.4729 1.5597 10.5525
SJNB-5 GDSC1; GDSC2 2.4073 4.9297 1.5056 10.3034
KP-N-RT-BM-1 GDSC1; GDSC2 2.5815 5.9995 1.1386 11.854
SK-N-BE(2)-M17 GDSC1; GDSC2 2.9553 5.1388 2.0924 6.6904
SJNB-6 GDSC1; GDSC2 2.9801 4.5061 2.2303 4.482
SK-N-FI GDSC1; GDSC2; CTRP2; CCLE 2.9838 4.6846 2.8827 15.0803
SK-N-BE(2) CTRP2; CCLE 3.0126 4.7646 2.9778 20.3153
SK-N-AS GDSC2; CCLE 3.5826 6.944 1.7233 7.0397
SJNB-7 GDSC1; GDSC2 3.913 7.2749 1.8139 5.9696
GI-ME-N GDSC1; GDSC2 4.1329 9.8997 0.682 10.7834
KP-N-YN GDSC1; GDSC2; CTRP2 4.575 7.8015 3.7657 12.0494
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 2.1265 3.6112 2.1224 26.1151
SNU-1196 CTRP2 2.3979 4.0898 2.3845 24.3385
SNU-869 CTRP2 2.7332 6.8609 2.1789 24.0174
SNU-478 CTRP2 2.8343 4.1462 2.8288 21.4046
HuH-28 CTRP2 2.8781 4.4061 2.8636 21.1428
HuCC-T1 GDSC2; CTRP2; CCLE 3.0701 4.69 3.0444 18.6592
SNU-308 CTRP2 3.3311 4.395 3.3275 18.0885
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 GDSC1; GDSC2; CTRP2 1.5011 3.083 1.4985 28.3871
HMC-1-8 CTRP2; CCLE 1.5091 3.0796 1.5066 30.2232
COLO 824 GDSC1; GDSC2 1.5094 3.4464 1.3085 14.4404
Evsa-T GDSC1; GDSC2 2.0044 3.457 1.845 10.5517
CAL-51 GDSC2; CTRP2 2.2446 7.7362 1.3379 26.7045
MDA-MB-468 GDSC2; CTRP2; CCLE 2.267 4.2393 2.2407 23.6773
HCC1569 GDSC2; CCLE 2.2781 3.913 1.9805 9.0873
HCC1599 GDSC1; GDSC2 2.5339 5.0497 1.7374 11.1105
CAL-148 GDSC1; GDSC2; CTRP2 2.5495 5.5113 2.3615 23.93
Hs 578T GDSC2; CTRP2; CCLE 2.6363 4.2793 2.6208 21.3367
MCF-7 GDSC2; CTRP2; CCLE 2.66 4.7768 2.6042 21.3167
HCC1806 GDSC2; CTRP2; CCLE 2.7936 5.035 2.7126 20.5636
Hs 739.T CCLE 2.8185 4.724 1.9824 5.9826
HCC1143 GDSC2; CTRP2 2.8373 6.0932 2.531 21.0367
KPL-1 CTRP2 2.8887 3.7537 2.8885 21.0245
HCC1395 GDSC2; CTRP2; CCLE 2.9402 4.8061 2.8974 20.8252
HCC1954 GDSC2; CTRP2; CCLE 2.9498 4.2405 2.9438 19.3484
MDA-MB-231 GDSC2; CTRP2 2.9565 5.114 2.8753 19.5468
Hs 578Bst CTRP2 2.9622 4.5878 2.9396 20.61
CAL-85-1 GDSC2; CTRP2; CCLE 2.9695 5.0311 2.9012 19.424
ZR-75-1 CTRP2; CCLE 2.9894 5.2811 2.8835 20.7146
MFM-223 GDSC1; GDSC2 3.0875 5.4457 2.0588 6.5294
BT-549 GDSC2; CTRP2; CCLE 3.2134 5.6719 2.8455 13.5249
AU565 GDSC2; CTRP2; CCLE 3.231 4.4859 3.2227 17.5994
HCC2157 GDSC1; GDSC2 3.2455 4.5619 2.6372 3.422
HCC1428 GDSC2; CTRP2 3.3388 4.4463 3.3057 11.4754
MDA-MB-453 GDSC2; CTRP2; CCLE 3.4407 4.4375 3.4378 16.2724
CAL-120 GDSC2; CTRP2 3.5197 4.4482 3.5176 15.7767
CAMA-1 GDSC2; CTRP2; CCLE 3.5884 4.6097 3.5837 15.3554
HDQ-P1 GDSC2; CTRP2; CCLE 3.6018 5.6506 3.475 15.6664
JIMT-1 GDSC2; CTRP2 3.6407 4.6572 3.6356 15.0305
HCC1937 GDSC2; CTRP2 3.6517 5.2402 3.6007 15.1075
HCC1500 GDSC1; GDSC2; CTRP2 3.7066 4.3649 3.7063 14.6035
SK-BR-3 CTRP2; CCLE 3.7078 4.6714 3.7035 15.581
T-47D GDSC2; CTRP2; CCLE 3.757 6.5725 3.3863 15.5289
HCC1187 GDSC1; GDSC2; CCLE 3.7989 8.873 0.9331 10.3003
MDA-MB-415 GDSC2; CCLE 3.8434 5.7607 2.505 2.879
HCC70 GDSC2; CCLE 3.8472 6.4351 2.1785 4.3858
BT-474 GDSC1; GDSC2; CTRP2; CCLE 3.8824 4.8185 3.8771 13.5212
EFM-192A GDSC2; CTRP2 3.9055 5.6307 3.6036 8.6897
HCC2218 GDSC1; GDSC2; CTRP2 3.9093 4.8082 3.9049 14.2388
HCC38 GDSC2; CTRP2 3.924 5.7663 3.5698 8.7684
HCC1419 GDSC2; CTRP2 4.0421 5.0032 4.0332 12.5351
MDA-MB-361 GDSC2; CTRP2 4.1444 6.4026 3.8631 12.8063
EFM-19 GDSC2; CCLE 4.1632 7.4476 1.9112 5.071
MDA-MB-436 GDSC2; CCLE 4.2 6.073 2.5911 1.9583
UACC-812 GDSC1; GDSC2; CCLE 4.2208 6.2867 2.5049 2.5558
MRK-nu-1 GDSC1; GDSC2 4.2422 7.4454 1.9676 4.679
BT-483 GDSC2 4.411 7.7068 1.9572 5.7466
OCUB-M GDSC1; GDSC2 4.5198 8.0899 1.8472 4.7799
MDA-MB-175-VII GDSC2; CCLE 4.5623 7.5769 2.118 3.8974
MDA-MB-157 GDSC2; CTRP2; CCLE 4.5638 6.8613 3.7098 6.6123
HCC202 CTRP2 4.5667 6.2438 4.0115 5.7436
BT-20 GDSC2; CTRP2; CCLE 4.6517 5.8616 4.5702 8.963
YMB-1-E GDSC2 4.6564 8.336 1.5536 4.821
MDA-MB-330 GDSC2 4.7676 7.3951 2.3266 2.3512
ZR-75-30 GDSC2; CTRP2; CCLE 5.1936 7.2327 4.6483 7.2643
UACC-893 GDSC2 5.2011 6.9917 2.7174 0.6861
BT 239 CTRP2 1.3495 4.0874 1.2932 31.4654
BT 271 CTRP2 1.8068 3.9303 1.783 28.311
BT 172 CTRP2 1.957 4.0901 1.9286 27.3263
BT 286 CTRP2 1.9946 3.6816 1.9868 27.0063
BT 112 CTRP2 2.075 3.235 2.0712 21.2083
BT 131 CTRP2 2.089 4.14 2.0624 26.4407
BT 416 CTRP2 2.1077 2.989 2.1076 26.2271
BT147 CTRP2 2.1423 4.401 2.0971 26.1485
BT 245 CTRP2 2.4676 3.9711 2.4603 23.8537
BT 330 CTRP2 2.5808 3.7765 2.579 23.0809
BT 145 CTRP2 2.5835 4.7935 2.4228 18.1614
BT 231 CTRP2 2.6399 4.7136 2.59 22.8497
BT164 CTRP2 2.6525 4.5222 2.5558 17.4277
BT 504 CTRP2 2.6586 3.6325 2.6582 22.5581
BT 340 CTRP2 2.8261 4.6926 2.7885 21.5671
BT 440 CTRP2 2.9211 3.8739 2.9205 20.8098
BT 228 CTRP2 2.9653 4.7806 2.9264 20.6444
BT 320 CTRP2 2.9782 4.5114 2.9611 20.4847
BT 482 CTRP2 2.9854 4.5207 2.9681 20.4374
BT 428 CTRP2 2.9872 4.1083 2.9847 20.3759
BT 359 CTRP2 2.9906 5.4154 2.86 20.7927
BT 333 CTRP2 3.0524 4.0512 3.0511 19.9376
BT 232 CTRP2 3.0803 4.7677 3.0486 19.8539
BT 216 CTRP2 3.1545 4.4595 3.1455 19.283
BT 422 CTRP2 3.2112 4.7452 3.1875 18.9549
BT 139 CTRP2 3.28 5.0547 3.229 18.5893
BT 187 CTRP2 3.3183 4.73 3.3001 18.2224
BT 159 CTRP2 3.3837 4.0144 3.3836 17.7263
BT 328 CTRP2 3.4563 5.0455 3.417 17.3753
BT 498 CTRP2 3.5361 6.4258 3.1941 17.9232
BT 224 CTRP2 3.7013 5.4483 3.4513 10.5486
BT 444 CTRP2 3.7201 5.3151 3.6633 15.6775
BT 179 CTRP2 3.8114 5.2295 3.772 15.0099
⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 2.5579 3.8666 2.5545 23.2387
Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D283 Med GDSC1; GDSC2; CTRP2 0.7012 2.66 0.6968 33.3889
H4 GDSC2; CCLE 0.9829 3.9108 0.5872 19.2004
PFSK-1 GDSC2 1.0758 6.8366 -0.5358 23.5967
MOG-G-UVW GDSC2 1.622 6.2473 0.2798 23.7282
GI-1 GDSC1; GDSC2; CCLE 1.8736 4.5292 1.3031 13.2978
DK-MG GDSC2; CTRP2; CCLE 2.0111 7.1937 0.9732 23.9463
A-172 GDSC2; CTRP2; CCLE 2.0671 4.1103 2.0416 24.9237
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 2.0879 5.4442 1.1142 13.5218
D-247MG GDSC1; GDSC2 2.2648 5.945 0.8775 14.2713
Hs 683 GDSC2; CTRP2; CCLE 2.2649 4.0998 2.247 25.2396
SF539 GDSC1; GDSC2; CTRP2 2.463 4.3536 2.4366 22.4537
D-336MG GDSC1; GDSC2 2.5134 3.8359 2.13 6.4599
KG-1-C CTRP2 2.5408 3.8627 2.5373 23.3531
GOS-3 CTRP2 2.5514 4.7028 2.4976 23.4525
D-423MG GDSC2 2.7027 5.149 1.6687 8.4833
LN-18 GDSC2; CTRP2; CCLE 2.7045 4.585 2.6706 20.9689
D-566MG GDSC2 2.7392 4.3869 2.0787 6.0331
YH-13 GDSC2; CTRP2 2.7636 4.9743 2.6892 20.7297
M059K CTRP2 2.7917 4.654 2.756 21.79
D-245MG GDSC2 2.7979 5.4702 1.5926 8.6468
KINGS-1 GDSC1; GDSC2 2.8158 12.7803 -1.8353 23.6361
U-118MG GDSC2; CTRP2; CCLE 2.8291 4.8482 2.7751 20.2548
GMS-10 CTRP2; CCLE 2.852 4.2328 2.8442 21.2943
GB-1 GDSC1; GDSC2; CTRP2; CCLE 2.8762 4.3091 2.8662 19.8208
SF295 GDSC2; CTRP2; CCLE 2.9223 5.4106 2.7869 21.2641
TM-31 CTRP2 2.9226 4.8077 2.8786 20.9464
KNS-60 CTRP2; CCLE 2.9493 6.2242 2.3546 17.2833
D-502MG GDSC1; GDSC2 2.9661 5.6314 1.656 7.8222
AM-38 GDSC1; GDSC2 2.9731 5.2474 2.055 6.8222
SW1088 GDSC2; CTRP2; CCLE 2.9946 5.0846 2.9205 19.286
ONS-76 GDSC1; GDSC2; CTRP2; CCLE 2.9994 4.6728 2.972 19.1064
YKG-1 GDSC2; CCLE 3.0052 5.1084 1.9501 5.6761
SF268 GDSC1; GDSC2; CTRP2 3.0125 4.8369 2.9704 19.0713
LN-229 GDSC2; CTRP2; CCLE 3.0337 4.8308 2.9935 18.9331
SNU-201 CTRP2 3.0663 4.3545 3.0591 19.8647
SF126 GDSC1; GDSC2; CTRP2; CCLE 3.0932 4.501 3.0805 19.7037
KNS-42 GDSC1; GDSC2; CCLE 3.1235 6.177 1.5132 7.7515
GaMG GDSC2; CTRP2; CCLE 3.1244 4.5718 3.1089 18.288
SNU-489 CTRP2 3.1268 4.3085 3.1221 19.4532
NMC-G1 GDSC1; GDSC2; CTRP2 3.138 4.4764 3.1278 19.3967
Onda 10 GDSC1; GDSC2 3.1389 4.6148 2.3052 3.6459
Becker GDSC1; GDSC2; CTRP2 3.1643 9.6899 1.4882 23.732
SK-MG-1 GDSC2 3.2116 5.1254 2.3267 4.972
SNU-1105 CTRP2 3.2291 4.2701 3.2267 18.7639
42-MG-BA GDSC2; CTRP2; CCLE 3.2329 5.6827 3.0668 18.0994
D-542MG GDSC2 3.262 4.8666 2.275 3.5283
SNB-75 GDSC1; GDSC2; CTRP2 3.2965 5.7045 3.1311 18.8786
SNU-466 CTRP2 3.3413 3.968 3.3412 18.0089
KNS-81 CTRP2; CCLE 3.388 5.5963 3.2543 18.1577
Daoy GDSC2; CTRP2; CCLE 3.4213 4.4191 3.4185 16.3934
D-263MG GDSC1; GDSC2 3.44 5.683 2.2383 4.8939
CAS-1 GDSC1; GDSC2; CCLE 3.4501 5.9989 2.0887 5.5825
CCF-STTG1 CTRP2 3.4676 5.1582 3.2912 11.9199
MOG-G-CCM GDSC2; CCLE 3.4691 6.0092 2.0989 6.1008
T98G GDSC2; CTRP2; CCLE 3.5376 5.478 3.4399 15.9717
KALS-1 GDSC1; GDSC2; CTRP2; CCLE 3.6068 6.0357 3.3866 15.948
LNZTA3WT4 GDSC2 3.6355 6.006 2.2314 5.8553
U-87MG ATCC GDSC1; GDSC2; CTRP2; CCLE 3.6401 7.5214 2.9089 17.5313
M059J GDSC2; CCLE 3.7158 5.7995 2.3941 3.6179
DBTRG-05MG GDSC2; CTRP2; CCLE 3.7396 5.344 3.6799 14.5865
8-MG-BA GDSC1; GDSC2; CTRP2; CCLE 3.778 5.7535 3.644 14.5907
U-251MG GDSC2; CTRP2 3.8017 4.8615 3.7926 14.0371
1321N1 CCLE 3.8267 7.1357 1.5741 5.893
Onda 11 GDSC1; GDSC2 3.8494 5.8115 2.2233 2.6601
D-392MG GDSC2 3.8874 8.1642 1.3544 8.1683
SW1783 GDSC2; CTRP2 3.902 6.0015 3.7179 14.9156
KNS-81-FD GDSC1; GDSC2 3.9658 7.8635 1.3186 7.3826
SNU-626 CTRP2 3.9773 5.186 3.9522 13.8558
LN-405 GDSC2 4.6468 8.6987 1.6414 5.5065
⏷ Show the Full List of 69 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1; GDSC2 2.7371 4.2237 2.3236 6.1917
TGBC24TKB GDSC1; GDSC2 2.7383 4.4282 2.2301 6.6152
TGBC1TKB GDSC1; GDSC2 3.7344 5.2609 2.671 2.9593
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP2; CCLE -0.3035 2.2727 -0.3139 42.3207
JHUEM-7 CTRP2 2.0268 3.0672 2.0252 21.5443
JHUEM-1 CTRP2 2.1496 3.182 2.1494 25.9483
RL95-2 GDSC1; GDSC2; CTRP2; CCLE 2.2003 4.5499 2.1431 24.1925
HEC-1-B CTRP2; CCLE 2.6704 4.2725 2.6563 22.5255
AN3-CA GDSC2; CTRP2; CCLE 2.7597 4.9168 2.6928 20.7299
HEC-59 CTRP2; CCLE 2.7737 5.2877 2.6494 22.2149
ESS-1 GDSC2; CTRP2; CCLE 2.7743 4.6613 2.737 20.5436
JHUEM-3 CTRP2 2.8363 4.8528 2.7823 21.5554
HEC-6 CTRP2; CCLE 3.2492 4.496 3.241 18.6493
HEC-50B CTRP2 3.2699 7.0301 2.6999 20.5314
HEC-1-A CTRP2; CCLE 3.3464 4.7224 3.3298 18.0302
EN GDSC2; CTRP2; CCLE 3.3951 5.1284 3.342 16.7168
HEC-151 CTRP2; CCLE 3.4638 5.2048 3.405 17.3916
HEC-108 CTRP2 3.5146 4.8137 3.4985 16.9079
HEC-251 CTRP2; CCLE 3.5897 4.6883 3.5824 16.378
EFE-184 CTRP2; CCLE 3.6565 4.7148 3.6498 15.9307
MFE-296 GDSC2; CTRP2; CCLE 3.6645 5.0454 3.6367 14.9534
HEC-265 CTRP2; CCLE 3.6935 4.7504 3.6863 15.6861
KLE GDSC1; GDSC2; CTRP2; CCLE 3.8962 4.9937 3.8829 13.4602
MFE-280 GDSC2; CCLE 4.017 6.6865 2.1778 4.0915
TEN CCLE 4.1566 6.731 1.9877 3.1871
MFE-319 GDSC2; CTRP2; CCLE 4.1641 5.3117 4.1363 11.833
Ishikawa (Heraklio) 02 ER- CTRP2; CCLE 4.3981 5.847 4.2975 11.3158
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KMRC-2 CTRP2; CCLE 2.4026 3.5435 2.4016 24.2655
KTCTL-26A GDSC2 2.52 4.381 1.8777 7.8488
KTCTL-140 GDSC2 2.5626 3.7262 2.2295 5.7427
KMRC-3 CTRP2 2.6712 3.6374 2.6707 22.4744
KTCTL-13 GDSC2 2.6738 5.3748 1.5309 9.3549
A-704 GDSC1; GDSC2 2.6752 5.6612 1.5776 9.8092
UO-31 GDSC2; CTRP2 2.7063 4.3153 2.6912 22.2894
A-498 GDSC1; GDSC2; CTRP2 2.7071 5.7513 2.4779 21.5902
CAL-54 GDSC2 2.7205 5.6157 1.642 9.3925
NCC010 GDSC2 2.7727 4.309 2.1476 4.6859
TUHR10TKB CTRP2 2.8176 3.852 2.8166 21.5004
769-P GDSC2; CTRP2; CCLE 2.8276 3.6094 2.8275 20.0936
SW13 GDSC2 2.8658 5.2039 1.9782 7.4504
TUHR4TKB CTRP2 2.8791 4.006 2.8769 21.0951
HA7-RCC GDSC1; GDSC2 2.9282 4.3537 2.2624 3.7534
BB65-RCC GDSC1; GDSC2 2.9433 4.0461 2.429 3.4384
KTCTL-195 GDSC2 2.9787 5.2802 2.0438 6.8615
SNU-1272 CTRP2 3.0057 5.3838 2.8823 20.667
NCC021 GDSC2 3.0315 5.0817 1.9853 5.7559
VMRC-RCW GDSC2; CTRP2; CCLE 3.0418 4.6631 3.017 20.087
ACHN GDSC2; CTRP2; CCLE 3.1025 5.7085 2.9189 18.9714
RXF 393L GDSC1; GDSC2 3.1338 4.9871 2.1156 4.0138
LB2241-RCC GDSC1; GDSC2 3.1547 4.8564 2.1974 4.2255
KMRC-20 GDSC2; CTRP2 3.1709 4.236 3.1683 17.9569
SW156 GDSC2 3.1831 4.785 2.2551 3.8261
BFTC-909 GDSC2; CTRP2; CCLE 3.212 4.1011 3.2112 17.6945
OS-RC-2 GDSC1; GDSC2; CTRP2 3.2582 5.6244 3.1073 17.8913
LB996-RCC GDSC1; GDSC2 3.2834 5.8423 2.0295 6.2216
KMRC-1 GDSC2; CTRP2; CCLE 3.3158 4.7811 3.2938 18.2522
786-O GDSC2; CTRP2; CCLE 3.4058 4.9997 3.3686 16.5992
TUHR14TKB CTRP2 3.4202 6.486 3.0488 39.5312
KTCTL-1M GDSC2 3.6108 5.5255 2.2029 3.2016
KTCTL-21 GDSC2 3.7797 6.0843 2.0493 3.7208
RCC10RGB GDSC1; GDSC2; CTRP2 3.869 4.9732 3.8559 13.6293
TK-10 GDSC1; GDSC2 4.0334 6.1691 2.4387 2.8728
LB1047-RCC GDSC1; GDSC2 4.0558 6.4669 2.0475 3.2383
VMRC-RCZ GDSC2; CTRP2; CCLE 4.5333 6.09 4.3826 9.9344
Caki-2 CTRP2; CCLE 4.5538 5.7152 4.2459 4.7582
Caki-1 GDSC2; CTRP2 4.7441 6.1497 4.5952 9.1875
SN12C GDSC2 4.7457 6.926 2.5225 1.5953
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 62 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CL-34 CTRP2 -2.8976 2.7934 -3.0567 58.5284
KM12 GDSC1; GDSC2; CTRP2 -0.8049 3.1799 -0.8861 42.9669
SW48 GDSC2; CTRP2; CCLE 0.4339 2.4646 0.4297 35.0579
SNU-175 GDSC2; CTRP2 1.0643 3.2345 1.0516 31.1469
SK-CO-1 GDSC2; CTRP2; CCLE 1.0645 3.1279 1.0552 31.1353
LoVo GDSC2; CTRP2 1.2063 5.1754 0.9737 30.9468
GP2d CTRP2 1.4016 4.579 1.1856 26.7927
LS513 GDSC1; GDSC2; CTRP2; CCLE 1.5987 3.09 1.5968 27.7752
SW948 GDSC2; CTRP2 1.6059 3.6548 1.5901 27.7737
HT115 GDSC2; CTRP2 1.6519 3.3428 1.6468 27.4531
COLO205 GDSC2; CTRP2; CCLE 1.717 3.2135 1.7147 27.0374
NCI-H716 GDSC1; GDSC2; CTRP2 1.7615 4.2714 1.6393 22.2898
SNU-407 GDSC2; CTRP2 1.933 4.2679 1.8895 25.8181
GP5d GDSC2 1.9722 4.7806 1.2972 13.029
HCT 116 GDSC2; CTRP2; CCLE 2.002 3.8259 1.9894 25.2896
SNU-C1 GDSC1; GDSC2; CTRP2 2.0142 3.2614 2.0133 25.1767
SNU-C2A CTRP2; CCLE 2.1257 4.9793 2.0045 26.5185
HT-29 GDSC2; CTRP2; CCLE 2.1293 3.8144 2.12 24.4841
CL-11 GDSC1; GDSC2; CTRP2 2.2387 5.075 2.11 24.1829
COLO 320 CTRP2; CCLE 2.2415 4.4718 2.1947 25.4929
COLO 320HSR GDSC1; GDSC2 2.2697 3.8393 2.0001 9.0287
NCI-H508 GDSC2; CTRP2 2.2796 4.9206 2.179 25.423
CCK-81 GDSC2; CTRP2; CCLE 2.3301 4.3586 2.2976 23.3032
SNU-1033 CTRP2 2.336 4.8077 2.2557 24.9779
RKO GDSC1; GDSC2; CTRP2; CCLE 2.4465 4.8531 2.3674 22.7253
SW620 GDSC2; CTRP2; CCLE 2.4534 5.0628 2.3432 22.7823
HT-55 GDSC2; CTRP2 2.466 4.4385 2.4333 22.4549
RCM-1 [Human ESC] GDSC2; CTRP2 2.4973 4.6968 2.3513 17.4739
SNU-283 GDSC2 2.5278 5.6128 1.2819 11.2018
SNU-1040 GDSC2 2.5608 7.4735 0.5821 14.7086
NCI-H747 GDSC1; GDSC2; CTRP2; CCLE 2.5698 4.6321 2.5246 21.8465
CaR-1 GDSC2 2.5978 5.2282 1.714 9.376
SW403 CCLE 2.6539 4.2445 2.0701 5.9716
COLO201 CTRP2; CCLE 2.6594 4.0687 2.6529 22.5729
LS1034 GDSC1; GDSC2; CTRP2 2.6921 3.9957 2.67 15.7466
LS411N GDSC1; GDSC2; CTRP2; CCLE 2.7291 4.0032 2.7253 20.7204
HCT 15 GDSC2; CTRP2; CCLE 2.756 5.2787 2.4793 16.2232
SNU-C5 GDSC2; CTRP2 2.7587 5.6189 2.5652 21.1498
HCC-56 CTRP2; CCLE 2.7893 4.3917 2.7727 21.7413
MDST8 GDSC1; GDSC2; CTRP2 2.8984 4.7459 2.8594 19.774
OUMS-23 CTRP2 2.8993 3.4734 2.8993 20.9533
C2BBe1 GDSC1; GDSC2; CTRP2; CCLE 2.9401 4.6415 2.9125 19.4772
SW480 CCLE 2.9545 5.5919 1.6659 7.3422
T84 GDSC2; CTRP2; CCLE 2.9768 4.6381 2.9511 19.2422
HCC2998 GDSC2 3.0202 4.6839 2.3756 5.1981
LS180 GDSC2; CTRP2 3.0321 5.2566 2.9337 19.1307
SW1116 GDSC2 3.2309 5.6229 2.0947 6.0289
LS123 GDSC1; GDSC2; CTRP2; CCLE 3.243 5.1537 3.1762 17.7111
SW1417 GDSC2; CTRP2; CCLE 3.2593 6.0314 3.0084 18.2188
SW1463 GDSC2 3.2684 5.853 2.0115 6.34
SW626 GDSC2 3.3056 5.6338 2.1524 5.5891
COLO 678 GDSC2; CTRP2; CCLE 3.344 6.0139 2.8566 13.1141
DLD-1 CTRP2 3.3605 4.7492 3.3426 17.9407
SNU-C2B GDSC1; GDSC2; CCLE 3.4436 6.1648 2.0005 6.0141
SW837 GDSC2 3.4582 5.7675 2.2107 4.9868
SNU-61 GDSC2; CTRP2 3.6097 5.2861 3.5494 15.3998
CW-2 GDSC1; GDSC2; CTRP2 3.6464 5.3753 3.5751 15.2064
HCT 8 CTRP2 3.7296 4.9502 3.7126 15.4785
DiFi GDSC2 4.2284 7.6396 1.8639 5.1775
SNU-C4 CTRP2 4.3882 5.0594 4.3855 11.0426
SNU-81 GDSC2 4.4217 6.8128 2.3857 2.5423
SNU-503 CTRP2 4.7315 7.0451 4.2533 10.5188
⏷ Show the Full List of 62 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 3.0935 5.5387 2.0179 6.709
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-182 CTRP2; CCLE 1.2393 4.1199 1.1738 32.2294
HuH-6 CTRP2 1.9121 3.58 1.9056 27.5516
Li-7 CTRP2 2.2554 3.7585 2.2501 25.2604
SNU-761 CTRP2 2.2635 8.513 0.668 25.9436
JHH-1 GDSC2; CTRP2 2.278 3.1288 2.2779 23.5263
Hep-G2 CTRP2; CCLE 2.4947 4.6814 2.44 23.8332
Hep 3B2.1-7 GDSC2; CTRP2; CCLE 2.4952 3.9239 2.4897 22.1867
HLF CTRP2; CCLE 2.5816 3.6775 2.5806 23.0728
JHH-5 CTRP2; CCLE 2.649 4.8522 2.5833 22.8431
SNU-423 GDSC2; CTRP2; CCLE 2.8208 4.669 2.7852 20.2481
HuH-1 GDSC2; CTRP2; CCLE 2.8658 5.0746 2.7841 20.1149
JHH-7 GDSC2; CCLE 3.0804 5.0702 2.2391 5.6939
SNU-449 GDSC2; CTRP2; CCLE 3.2024 4.7126 3.1141 12.5759
SNU-878 CTRP2 3.2042 4.7862 3.1769 19.0137
SNU-387 GDSC2; CTRP2; CCLE 3.2519 4.9317 3.2133 17.565
JHH-2 GDSC2; CTRP2; CCLE 3.2934 5.3513 3.199 17.4859
JHH-6 GDSC2; CTRP2; CCLE 3.3483 4.1702 3.3477 16.8425
SNU-398 GDSC2; CTRP2; CCLE 3.3746 5.583 3.2425 17.1026
HLE GDSC2; CCLE 3.4875 5.716 2.2599 4.6935
SK-HEP-1 GDSC2; CTRP2; CCLE 3.5602 5.6734 3.4249 15.9544
Huh-7 GDSC2 3.663 5.4125 2.5455 3.0069
Hep-G2/C3A GDSC2; CCLE 3.691 6.46 2.0489 5.2866
JHH-4 GDSC2; CTRP2; CCLE 3.8192 5.4725 3.7448 14.1377
SNU-886 CTRP2 3.8588 4.9957 3.8439 16.8799
PLC/PRF/5 CTRP2; CCLE 4.3413 5.4616 4.3064 11.4645
SNU-475 CTRP2; CCLE 4.5873 6.7458 4.2197 11.0457
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 226 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
EBC-1 GDSC2; CTRP2; CCLE -3.9613 -1.3599 -3.9618 62.4541
NCI-H1993 GDSC2 -1.2585 5.2253 -2.3006 37.6067
NCI-H3122 GDSC2 -0.6127 4.0778 -1.1999 31.7743
NCI-H2228 GDSC2; CTRP2; CCLE 0.5073 7.2935 -0.6622 33.8092
NCI-H847 GDSC1; GDSC2 0.669 2.4106 0.6151 25.9667
NCI-H524 GDSC1; GDSC2 0.7719 2.36 0.7306 19.3497
Lu-135 GDSC2 0.8916 2.9771 0.7553 18.8223
NCI-H211 GDSC1; GDSC2; CTRP2; CCLE 1.1229 2.941 1.1186 30.7549
NCI-H446 GDSC1; GDSC2; CTRP2 1.1625 3.7918 1.1227 30.6186
IST-SL1 GDSC1; GDSC2 1.1626 3.1067 0.9647 17.7097
NCI-H1184 CTRP2; CCLE 1.2417 3.8027 1.2044 32.1204
Lu-134-A GDSC1; GDSC2 1.2744 2.7961 1.1684 16.2392
A-427 GDSC2 1.2747 3.3563 1.009 14.4037
NCI-H82 GDSC1; GDSC2 1.2876 3.6861 0.9927 16.4951
NCI-H2171 GDSC1; GDSC2 1.3002 2.0847 1.2941 15.5302
LB647-SCLC GDSC1; GDSC2 1.3368 3.1748 1.1343 16.1473
SBC-3 GDSC2 1.4426 3.8806 1.0952 15.5533
HCC1588 CTRP2 1.4822 3.4062 1.4727 30.4257
RERF-LC-MS GDSC2; CTRP2; CCLE 1.5747 7.2168 0.8025 32.263
VMRC-LCD GDSC2; CTRP2; CCLE 1.6412 4.9734 1.3495 23.6874
Lu-99 CTRP2; CCLE 1.646 3.859 1.6208 29.3868
COR-L311 GDSC2 1.6561 3.3349 1.5005 13.1526
SBC-1 GDSC1; GDSC2 1.678 4.0882 1.163 14.6767
LCLC-97TM1 GDSC2; CTRP2 1.7039 4.279 1.6475 27.2902
NCI-H1341 GDSC2; CTRP2; CCLE 1.7146 4.3058 1.5822 24.2518
HCC44 GDSC2; CTRP2; CCLE 1.7629 3.7614 1.7466 26.7949
DV-90 CTRP2; CCLE 1.7728 4.12 1.7343 28.5869
NCI-H64 GDSC1; GDSC2 1.8065 4.3014 1.3262 17.2481
NCI-H1734 GDSC2; CTRP2 1.8268 4.1325 1.7897 28.2227
HCC2108 CTRP2 1.8355 4.8044 1.7206 28.4278
NCI-H292 GDSC2; CTRP2 1.8488 3.9373 1.8261 28.0276
DMS 273 GDSC2; CTRP2 1.8514 4.8107 1.7367 26.5554
Lu-65 GDSC1; GDSC2; CTRP2 1.854 4.0698 1.8229 26.2725
NCI-H1436 GDSC1; GDSC2 1.9127 3.5291 1.6362 11.295
LK-2 GDSC2 1.9265 6.4972 0.4613 16.9159
CPC-N GDSC1; GDSC2 1.9511 4.1975 1.5208 12.1056
NCI-H1770 GDSC1; GDSC2 1.9882 2.8961 1.9224 9.5394
NCI-H2461 GDSC2 2.0123 9.3194 -0.8277 22.0853
LC-2/ad GDSC1; GDSC2 2.0145 4.2428 1.443 11.9553
NCI-H358 GDSC2; CTRP2; CCLE 2.0158 4.6349 1.9372 25.413
NCI-H2286 CTRP2; CCLE 2.021 5.798 1.7183 27.838
NCI-H2810 GDSC2 2.025 4.5052 1.3347 10.5829
COR-L279 GDSC2 2.0258 4.6566 1.4064 15.9891
LXF 289 GDSC1; GDSC2; CTRP2 2.0289 3.8479 2.0161 25.1223
CAL-12T GDSC2; CTRP2; CCLE 2.0679 3.7516 2.0594 26.5206
NCI-H2009 GDSC2; CTRP2; CCLE 2.0743 4.3117 2.0339 26.585
NCI-H526 GDSC1; GDSC2; CTRP2 2.1027 4.317 2.0631 24.746
Lu-139 GDSC1; GDSC2 2.1124 3.4454 1.9663 9.6858
EMC-BAC-1 GDSC2 2.1178 5.5062 0.9527 14.3189
Ms-1 GDSC1; GDSC2 2.1237 4.3319 1.6469 11.0232
NCI-H1755 GDSC2; CTRP2 2.1479 4.3075 2.1113 24.454
HCC1833 CTRP2 2.1506 5.1567 2.0003 26.4529
NCI-H2023 GDSC2; CTRP2; CCLE 2.1584 6.456 1.6843 25.8186
NCI-H2106 CTRP2 2.1594 3.916 2.1471 25.9236
PC-14 GDSC2; CTRP2; CCLE 2.1716 3.8449 2.1622 24.2203
COR-L321 GDSC2 2.1835 4.3758 1.5524 10.7712
HCC95 CTRP2 2.2063 3.9292 2.1947 25.6088
NCI-H2081 GDSC1; GDSC2; CTRP2 2.2272 4.4275 2.1839 25.5763
NCI-H2731 GDSC2 2.2273 5.1392 1.3938 11.8591
NCI-H69 GDSC1; GDSC2; CTRP2 2.228 5.1344 2.0879 25.9024
NCI-H2227 GDSC2 2.2615 5.6784 1.0046 11.4924
COR-L32 GDSC2 2.263 4.1719 1.7256 9.5447
A-549 GDSC2; CTRP2; CCLE 2.283 4.2109 2.2592 23.5696
NCI-H810 GDSC2; CTRP2; CCLE 2.2934 4.3368 2.261 23.5318
NCI-H2085 GDSC2; CTRP2; CCLE 2.3076 4.6308 2.2476 23.5314
NCI-H1963 GDSC1; GDSC2 2.3091 4.7882 1.6365 10.5252
HCC15 GDSC2; CTRP2; CCLE 2.3294 4.4782 2.2866 23.3402
NCI-H1792 GDSC2; CTRP2; CCLE 2.3441 4.4339 2.306 23.2331
NCI-H2126 CTRP2 2.3662 4.6587 2.3065 24.706
NCI-H889 CTRP2 2.3663 6.4632 1.9086 26.0933
NCI-H2029 GDSC2; CTRP2 2.3786 4.2099 2.3132 17.9831
NCI-H1304 GDSC1 2.3822 3.7938 0.5184 0.8837
HARA [Human squamous cell lung carcinoma] GDSC2; CTRP2; CCLE 2.3977 4.7556 2.3282 22.9991
NCI-H647 GDSC2; CTRP2; CCLE 2.4141 3.8477 2.4091 24.2025
SK-LU-1 GDSC2; CTRP2; CCLE 2.4225 4.5809 2.3745 22.7753
NCI-H727 GDSC2; CTRP2; CCLE 2.4376 4.0771 2.4258 22.5664
COLO 668 GDSC1; GDSC2; CTRP2 2.4438 4.5815 2.3969 22.6387
MOR/CPR CTRP2; CCLE 2.4551 3.6798 2.4534 23.9181
HCC33 GDSC1; GDSC2 2.4613 4.1448 1.934 7.7234
NCI-H1437 GDSC2 2.4681 4.8048 1.6234 9.4477
NCI-H187 GDSC1 2.4748 4.1091 0.4349 1.1991
COLO 677 CCLE 2.4904 4.3611 1.859 7.5794
HOP-92 GDSC2; CTRP2 2.4983 5.1857 2.3705 22.5591
COLO 699 CTRP2; CCLE 2.5032 5.2861 2.3572 24.0913
NCI-H2405 GDSC2; CTRP2 2.5035 4.4508 2.4714 22.2187
DMS 454 CTRP2 2.5093 5.355 2.3504 24.0958
DMS 79 GDSC1; GDSC2; CTRP2 2.5138 3.7045 2.5122 22.0581
NCI-H1435 GDSC2; CTRP2 2.5607 5.0049 2.4676 22.0569
HCC1195 CTRP2 2.589 7.9287 1.6321 26.3806
DMS 114 GDSC1; GDSC2; CTRP2; CCLE 2.5957 4.8155 2.5313 21.7459
SBC-5 GDSC2; CTRP2; CCLE 2.6022 7.8393 1.6809 24.5786
NCI-H1155 GDSC1; GDSC2; CTRP2; CCLE 2.6059 4.8951 2.5317 21.7137
COR-L303 GDSC2 2.6147 3.8638 2.2163 5.6426
EPLC-272H GDSC2; CTRP2 2.6224 4.9305 2.5446 21.6224
NCI-H128 GDSC1 2.6237 5.1041 0.0909 3.0023
HCC2279 CTRP2 2.6273 4.2643 2.6122 22.8158
COR-L95 GDSC1; GDSC2; CTRP2 2.6326 4.7657 2.4828 17.7698
NCI-H23 GDSC1; GDSC2; CTRP2; CCLE 2.642 5.1577 2.5304 21.6093
NCI-H510A GDSC1; GDSC2 2.6423 4.2997 2.0324 6.591
LUDLU-1 CTRP2; CCLE 2.6565 4.0369 2.6508 22.5896
NCI-H2795 GDSC2 2.664 6.4624 1.1746 11.7192
Lu-99A GDSC2 2.6751 5.4773 1.667 9.3923
HCC78 GDSC2; CTRP2; CCLE 2.6849 7.3781 1.9435 23.4643
SW1271 GDSC2; CTRP2; CCLE 2.6955 4.463 2.6709 20.9958
EMC-BAC-2 GDSC2 2.7143 6.3463 1.2777 11.113
NCI-H2122 GDSC2; CTRP2; CCLE 2.7198 3.9281 2.7172 20.7747
NCI-H2110 GDSC2; CTRP2 2.7314 4.5501 2.7016 22.1718
NCI-H290 GDSC2 2.7494 6.2853 1.1441 11.3413
NCI-H2141 GDSC1; GDSC2 2.7778 4.7556 2.1131 7.0479
NCI-H1648 GDSC1; GDSC2; CCLE 2.7823 5.2011 1.9019 8.9048
DMS 53 GDSC2; CTRP2 2.8005 4.2773 2.7898 20.296
NCI-H2291 GDSC2; CTRP2 2.8106 4.5865 2.7816 21.6413
NCI-H838 GDSC2; CTRP2 2.8193 4.7562 2.6882 16.3673
NCI-H1395 CTRP2 2.8212 18.4853 -3.031 36.543
NCI-H2804 GDSC2 2.8254 6.4845 1.1102 9.5885
NCI-H841 GDSC2; CTRP2 2.8324 6.2628 2.477 21.2334
NCI-H650 GDSC2; CTRP2; CCLE 2.8423 4.9566 2.7756 20.213
SK-MES-1 GDSC2; CCLE 2.8428 4.9577 2.077 7.0467
NCI-H3255 GDSC2; CCLE 2.8446 3.8629 2.4331 3.127
HCC366 GDSC2; CTRP2 2.8456 5.1164 2.756 20.2665
NCI-H520 GDSC2; CTRP2; CCLE 2.8591 4.2845 2.8496 19.926
COR-L23 GDSC2; CCLE 2.8786 4.5743 2.2965 5.9305
Calu-3 GDSC2; CTRP2; CCLE 2.8819 4.3141 2.8718 19.7855
RERF-LC-Ad2 CTRP2 2.8888 4.7642 2.7621 15.8549
NCI-H1838 GDSC1; GDSC2; CTRP2 2.9176 4.4969 2.8993 20.8927
LK2 CTRP2 2.9303 5.009 2.8624 20.977
NCI-H2030 GDSC2; CTRP2; CCLE 2.9418 5.0621 2.8672 20.9232
BEN GDSC2; CTRP2 2.9422 4.3171 2.9335 20.6965
NCI-H1650 GDSC1; GDSC2; CTRP2; CCLE 2.9453 4.7803 2.9054 19.4842
NCI-H441 GDSC2; CTRP2; CCLE 2.959 5.6862 2.7678 19.8921
NCI-H345 GDSC1; GDSC2 2.9687 3.665 2.641 1.8182
LOU-NH91 GDSC2; CTRP2; CCLE 2.9711 4.7308 2.9373 19.3034
NCI-H1373 CTRP2; CCLE 2.9979 5.1873 2.9083 20.6012
NCI-H1666 GDSC1; GDSC2; CTRP2; CCLE 3.0235 4.5793 3.0039 18.931
NCI-H1385 CTRP2 3.0339 4.842 2.9925 20.1961
NCI-H250 GDSC2 3.0365 5.1924 1.9341 5.1061
NCI-H1563 GDSC2; CTRP2; CCLE 3.0497 5.69 2.8657 19.3021
NCI-H661 GDSC2; CTRP2; CCLE 3.0507 5.3531 2.9368 19.065
IST-SL2 GDSC1; GDSC2 3.0573 4.6926 2.201 3.7624
HOP-62 GDSC1; GDSC2; CTRP2 3.058 4.9188 3.0095 18.8076
NCI-H1573 GDSC2; CTRP2; CCLE 3.0604 5.0666 2.9934 20.107
NCI-H1568 GDSC2; CTRP2; CCLE 3.0683 4.7024 2.9706 13.5019
NCI-H2170 GDSC2; CTRP2; CCLE 3.0815 4.5655 3.0649 18.5591
NCI-H1944 GDSC2; CTRP2; CCLE 3.0849 4.7305 3.0567 18.5748
NCI-H2803 GDSC2 3.1114 5.4141 1.8845 5.1845
NCI-H748 GDSC1; GDSC2 3.116 6.6902 1.2507 9.747
ChaGo-K-1 GDSC2; CTRP2 3.1237 6.0469 2.8563 20.3925
NCI-H1688 GDSC2 3.1554 6.5649 1.5597 11.2647
NCI-H1703 GDSC2; CTRP2; CCLE 3.1669 6.4496 2.4937 16.0688
RERF-LC-A1 CTRP2; CCLE 3.1886 4.5928 3.1741 19.0741
NCI-H2087 GDSC2; CTRP2; CCLE 3.19 4.9826 3.1421 17.981
NCI-H1299 GDSC1; GDSC2; CTRP2; CCLE 3.1997 5.1889 3.1247 18.0077
NCI-H146 GDSC2 3.2506 5.5209 1.9418 5.4582
COR-L88 GDSC1; GDSC2 3.2588 5.7466 2.0566 7.9121
NCI-H1975 GDSC1; GDSC2; CTRP2; CCLE 3.2589 4.7736 3.2351 17.4741
HCC4006 CTRP2; CCLE 3.2625 5.4662 3.1445 18.9377
NCI-H2172 GDSC2; CTRP2; CCLE 3.275 5.5283 3.1458 18.894
UMC-11 GDSC2 3.2853 6.8889 1.5078 8.6905
Calu-6 GDSC1; GDSC2; CTRP2; CCLE 3.2991 5.1292 3.2395 17.3374
HCC1171 CTRP2 3.3027 6.8637 2.7944 20.0855
NCI-H1355 GDSC1; GDSC2; CTRP2; CCLE 3.3035 6.3224 2.9729 18.2147
NCI-H1048 GDSC2; CCLE 3.3098 5.8896 2.028 6.1708
NCI-H1581 GDSC1; GDSC2; CTRP2; CCLE 3.33 5.4308 3.2242 17.2946
NCI-H2066 GDSC2 3.3355 5.7379 2.1253 7.3005
LCLC-103H GDSC2; CTRP2; CCLE 3.3377 4.2206 3.3367 16.9099
NCI-H596 GDSC2 3.3566 7.7605 1.1315 10.3065
GLC-82 CCLE 3.3681 5.7921 1.8976 5.1175
NCI-H1915 GDSC2; CTRP2; CCLE 3.3767 4.536 3.37 16.6842
NCI-H1694 GDSC1; GDSC2; CTRP2; CCLE 3.3803 4.4873 3.3752 16.6566
RERF-LC-Ad1 CTRP2 3.3854 5.0599 3.3403 17.867
NCI-H1339 CTRP2; CCLE 3.3861 5.3568 3.298 18.0106
NCI-H322M GDSC1; GDSC2 3.4245 5.3617 2.3863 4.2243
HCC1438 CTRP2 3.4309 5.8201 3.2502 18.0386
RERF-LC-Sq1 GDSC2 3.4315 8.6488 0.7492 11.9167
NCI-H460 GDSC2; CTRP2; CCLE 3.4374 5.1264 3.3874 17.5374
SW1573 GDSC2; CTRP2; CCLE 3.451 6.411 3.1061 17.3446
NCI-H2373 GDSC2 3.4566 9.2075 0.4906 13.0372
Sq-1 CTRP2; CCLE 3.4743 4.5271 3.4699 17.1371
NCI-H2869 GDSC2 3.4746 5.8396 1.9537 4.1244
NCI-H2196 GDSC1; GDSC2; CTRP2 3.5024 4.763 3.4293 11.2754
SHP-77 GDSC1; GDSC2; CTRP2; CCLE 3.5056 4.8114 3.4893 15.9093
HCC2935 CTRP2; CCLE 3.5113 5.0212 3.4777 16.9892
NCI-H1693 GDSC2; CCLE 3.5267 5.7135 2.2922 4.4608
NCI-H1876 GDSC1; GDSC2 3.5413 7.6748 1.3255 9.0019
NCI-H1836 GDSC1; GDSC2 3.5423 5.2742 2.277 2.9269
NCI-H1105 GDSC2; CTRP2 3.5547 5.5439 3.4458 16.9603
NCI-H720 GDSC1; GDSC2 3.575 7.2115 1.3521 6.819
NCI-H1092 GDSC1; GDSC2; CTRP2; CCLE 3.5755 5.8002 3.1862 11.2072
HCC827 GDSC2; CTRP2; CCLE 3.5949 5.8281 3.427 15.8464
COR-L105 GDSC2; CTRP2; CCLE 3.6141 5.6475 3.4891 15.5839
NCI-H740 GDSC2 3.6241 6.2824 1.8454 5.1645
NCI-H226 GDSC1; GDSC2; CTRP2; CCLE 3.6499 8.8008 2.3784 19.4159
T3M-10 CTRP2; CCLE 3.6553 5.1092 3.6205 16.034
NCI-H209 GDSC1; GDSC2 3.6609 6.9112 1.8014 6.5132
NCI-H2342 GDSC2; CTRP2 3.6807 5.7487 3.5391 16.2368
NCI-H1781 GDSC2 3.7166 6.6777 1.9606 5.653
NCI-H196 GDSC2; CTRP2 3.7192 4.2612 3.7192 14.524
PaCa-3 GDSC2 3.742 6.3456 2.1443 6.1214
LC-1/sq GDSC2 3.748 6.6738 1.9864 5.4709
RERF-LC-KJ GDSC2 3.7553 6.4159 2.1196 4.8314
Lu-165 GDSC1; GDSC2 3.7995 6.5438 2.0896 4.8891
NCI-H2722 GDSC2 3.8018 6.6855 2.0214 5.2045
NCI-H1869 GDSC1; GDSC2; CTRP2; CCLE 3.8521 6.0015 3.6635 14.3113
NCI-H835 GDSC2 3.9128 7.7839 1.5622 9.2035
NCI-H522 GDSC2; CTRP2; CCLE 3.914 5.4225 3.855 13.4955
NCI-H1623 GDSC2; CTRP2 3.9366 6.4759 3.2788 9.8795
NCI-H2135 GDSC1; GDSC2 3.939 5.6717 2.3418 1.6144
LC-1/sq-SF CTRP2; CCLE 3.9488 5.0395 3.8501 8.1898
EKVX GDSC1; GDSC2; CTRP2 3.9573 5.5209 3.8853 13.2674
NCI-H2369 GDSC2 3.9796 6.4314 2.2753 3.7058
NCI-H322 CTRP2; CCLE 4.0944 6.2113 3.8685 13.7876
Calu-1 CTRP2; CCLE 4.1282 5.8224 4.0094 13.1771
NCI-H2444 GDSC2; CTRP2; CCLE 4.2265 5.5969 3.9576 6.9
IA-LM GDSC1; GDSC2; CTRP2; CCLE 4.2553 5.5793 3.9952 6.2164
NCI-H2591 GDSC2 4.4052 9.2731 1.1938 7.949
NCI-H1651 GDSC2; CCLE 4.4095 7.7368 1.9419 4.5261
ABC-1 GDSC2 4.416 6.7219 2.1445 1.8672
NCI-H1793 GDSC2; CTRP2; CCLE 4.4318 5.5597 4.3892 10.2086
NCI-H2595 GDSC2 4.5837 11.8247 0.0708 12.5971
NCI-H2818 GDSC2 4.6709 9.0286 1.4995 6.1076
NCI-H2347 GDSC2 4.7419 8.5512 1.7749 6.1354
NCI-H513 GDSC2 4.7683 8.0307 2.036 3.5786
Hs 229.T CCLE 4.8369 8.4119 1.6284 3.9116
KNS-62 GDSC2; CTRP2; CCLE 5.0178 5.9628 4.9453 6.6484
SW900 CCLE 5.9612 8.1652 2.2789 0.4385
Hs 888.Lu CTRP2 2.8811 4.7466 2.8411 21.2091
⏷ Show the Full List of 226 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 2.4337 5.242 1.5489 10.579
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Aska-SS CTRP2 -2.4194 2.9646 -2.5696 55.8037
Yamato-SS CTRP2 -0.8498 5.6979 -1.3877 46.5403
Tm87-16 CTRP2 -1.5382 3.3707 -1.6834 50.4818
Rh41 GDSC2; CTRP2 0.7779 2.2639 0.7774 32.8977
EW-8 GDSC1; GDSC2 0.903 1.8735 0.8993 18.2195
G-401 GDSC2; CTRP2; CCLE 1.8583 4.0858 1.7743 21.5129
Rh18 CTRP2 1.8721 4.9186 1.7416 28.2377
TE 617.T CTRP2; CCLE 1.9341 4.382 1.8797 27.5663
Hs 633.T GDSC2 2.0437 3.7617 1.7862 13.7794
SW982 GDSC1; GDSC2; CTRP2 2.0462 3.7126 2.0384 24.9983
Rh30 GDSC2; CCLE 2.0615 3.4586 1.9067 10.1041
Hs 729.T CTRP2; CCLE 2.4445 3.6623 2.4428 23.9886
STS-0421 GDSC2 2.4613 4.1478 1.9326 7.7312
KYM-1 GDSC1; GDSC2; CTRP2; CCLE 2.4937 4.4449 2.4617 22.2798
G-402 GDSC2; CTRP2; CCLE 2.5197 5.05 2.4166 22.3455
MES-SA GDSC2; CTRP2; CCLE 2.5264 5.1725 2.4032 22.3691
TTC-709 CTRP2 2.5468 4.3272 2.5255 23.3729
GCT GDSC2; CTRP2; CCLE 2.6036 4.4667 2.5748 21.5829
RD GDSC2; CTRP2; CCLE 2.995 5.0282 2.9288 19.2579
BT-12 CTRP2 3.1142 3.9076 3.1139 19.5224
SK-LMS-1 GDSC1; GDSC2; CTRP2; CCLE 3.1388 5.7852 2.9403 18.7947
HT-1080 GDSC2; CTRP2; CCLE 3.1573 4.1835 3.1553 18.04
BT-16 CTRP2 3.2052 4.3017 3.2018 18.9263
A-204 GDSC2; CTRP2; CCLE 3.4176 5.6836 3.2675 16.8936
VA-ES-BJ GDSC1; GDSC2 3.4687 8.918 0.6452 12.3111
SW684 GDSC1; GDSC2 3.6482 5.5722 2.4557 3.4543
RKN GDSC2; CTRP2; CCLE 3.8647 5.0345 3.8472 13.6703
SK-UT-1 GDSC1; GDSC2; CTRP2 4.1719 6.5744 3.835 12.8292
SW872 GDSC1; GDSC2 4.3884 7.8041 1.8953 4.7708
MFH-ino GDSC1; GDSC2 4.6985 8.9809 1.5412 7.5271
TE 441.T GDSC1; GDSC2; CTRP2 7.6607 9.1247 5.5537 0.3761
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SYO-1 CTRP2 0.9259 2.3926 0.9252 34.1026
Cancer Drug Sensitivity Data Curated from 49 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 1.536 4.1329 1.485 30.2064
COV434 CTRP2 1.1762 4.0296 1.1164 32.6306
A2780 GDSC2; CTRP2; CCLE 1.2257 3.97 1.174 30.2613
Caov-3 GDSC2; CTRP2 1.7281 4.5539 1.6414 29.0474
JHOS-4 GDSC2; CCLE 1.7397 4.0614 1.2386 14.0459
COV644 CTRP2 1.841 3.1503 1.84 28.0069
OV7 CTRP2 2.2925 3.981 2.2809 25.0343
SNU-119 CTRP2 2.3711 3.8992 2.364 24.4957
DOV13 GDSC2; CTRP2; CCLE 2.665 4.3776 2.6448 21.1722
HEY A8 CTRP2; CCLE 2.6677 4.2024 2.6566 22.5332
MCAS CTRP2; CCLE 2.6818 4.5356 2.651 22.5055
RMG-I GDSC2; CTRP2 2.705 5.4976 2.5334 22.8377
OVCAR-5 GDSC2; CTRP2 2.7122 5.132 2.6102 21.1397
COV362 CTRP2 2.8215 4.2195 2.8135 21.4984
OAW28 GDSC2; CTRP2 2.9142 5.4735 2.7655 20.0313
IGROV-1 GDSC2; CTRP2; CCLE 2.9509 5.5305 2.7936 19.8305
COV504 CCLE 3.0974 5.2913 1.9345 5.5356
OVK18 GDSC2; CTRP2 3.1532 4.8314 3.1193 18.1664
OVMANA CCLE 3.1741 4.8154 2.233 3.7428
SNU-8 CTRP2 3.2135 4.0233 3.2132 18.8607
ES-2 GDSC1; GDSC2; CCLE 3.2246 4.4988 2.6506 3.4067
ONCO-DG-1 CTRP2; CCLE 3.2425 4.8498 3.2115 18.771
TYK-nu GDSC2; CTRP2; CCLE 3.2591 4.8997 3.2241 17.5086
OC 314 GDSC2; CTRP2; CCLE 3.2694 4.2627 3.2675 18.4937
OVTOKO GDSC2; CTRP2; CCLE 3.2892 4.0206 3.2891 17.2102
TOV-21G GDSC2; CTRP2; CCLE 3.3232 5.2736 3.2441 17.2502
JHOS-2 GDSC2; CTRP2; CCLE 3.3792 4.7217 3.304 12.1623
Caov-4 GDSC2 3.3946 5.7618 2.162 6.9114
OVISE GDSC2; CTRP2 3.4193 4.6081 3.4109 16.4232
ES2 CTRP2 3.4467 4.7033 3.4346 17.3468
OVCAR-3 GDSC2; CCLE 3.4765 5.2062 2.5053 3.5535
OVSAHO CTRP2; CCLE 3.4783 4.0765 3.4783 17.0958
JHOC-5 CTRP2 3.5067 4.7541 3.4938 16.9498
OV-90 GDSC2; CTRP2; CCLE 3.539 5.4922 3.4387 15.9714
FU-OV-1 GDSC2; CTRP2; CCLE 3.5473 5.2343 3.4901 16.8302
Kuramochi GDSC1; GDSC2; CTRP2; CCLE 3.5619 4.9315 3.5391 15.5786
OVCAR-8 GDSC2; CTRP2; CCLE 3.6257 5.2434 3.5726 15.2768
OC 315 CCLE 3.7668 5.4538 2.338 2.0681
EFO-27 GDSC2; CTRP2; CCLE 3.8012 5.2259 3.7617 14.137
COV318 CCLE 3.8033 6.2116 2.0043 3.6935
OVKATE GDSC2 3.81 5.4433 2.6353 3.019
OVCAR-4 GDSC1; GDSC2; CTRP2; CCLE 3.9099 5.4961 3.8385 13.561
TOV-112D GDSC2; CTRP2; CCLE 3.9156 6.1596 3.6888 14.0447
SK-OV-3 GDSC2; CTRP2; CCLE 4.0578 5.2411 4.0315 12.4919
SNU-840 CTRP2 4.1566 5.3138 4.1281 12.673
OAW42 GDSC2; CTRP2 4.1631 5.3005 4.1365 11.8353
OV56 GDSC2; CTRP2 4.345 5.3781 4.3204 10.6929
EFO-21 GDSC2; CTRP2; CCLE 4.4172 5.5884 4.1611 5.1332
OC 316 CCLE 5.5348 7.1665 2.4731 0.2067
⏷ Show the Full List of 49 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H28 GDSC2; CTRP2; CCLE 2.1137 4.3048 2.0757 24.6724
IST-Mes2 CCLE 2.6695 4.5062 1.9564 6.535
MSTO-211H GDSC1; GDSC2; CTRP2; CCLE 2.8876 4.8583 2.836 19.8818
IST-Mes1 GDSC1; GDSC2; CTRP2; CCLE 2.9073 5.0479 2.8324 19.8336
MPP 89 GDSC1; GDSC2; CCLE 2.9409 6.7619 1.2749 10.5766
NCI-H2052 GDSC2; CTRP2; CCLE 3.1586 5.6138 3.0013 18.5341
NCI-H2452 GDSC2; CTRP2; CCLE 3.2013 5.8671 2.9883 19.6814
JL-1 CTRP2 3.8178 6.8219 3.0024 12.0916
ACC-MESO-1 CTRP2 4.0148 5.6187 3.9295 13.814
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
22Rv1 GDSC2; CTRP2; CCLE 2.1395 4.8967 2.0324 24.7324
VCaP GDSC1; GDSC2; CTRP2 2.2329 3.8332 2.2029 18.8326
LNCaP clone FGC GDSC1; GDSC2; CTRP2 3.0339 5.823 2.8167 19.5115
NCI-H660 GDSC2 4.3299 5.8008 2.4916 0.7847
DU145 GDSC2; CTRP2; CCLE 4.5078 6.1067 4.3501 10.1172
PC-3 GDSC2; CCLE 4.6567 8.5758 1.7069 5.1968
PaCa-3 CTRP2 5.0631 6.6633 4.7583 7.6584
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 1.9595 3.4895 1.9556 27.2273
A-253 GDSC1; GDSC2; CTRP2; CCLE 5.0059 7.5255 4.3264 8.9189
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1; GDSC2 0.8388 2.8781 0.6736 17.3349
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-620 CTRP2 -4.7398 -3.7089 -4.7398 71.8452
SNU-5 GDSC1; GDSC2; CTRP2 -4.2672 -1.259 -4.2687 64.2822
MKN45 GDSC2; CTRP2; CCLE -0.7744 5.3442 -1.2183 43.4043
IM95 GDSC2; CTRP2; CCLE -0.0466 5.2739 -0.4094 38.9722
Hs 746.T GDSC2; CTRP2; CCLE 0.6016 11.7346 -2.0365 39.5904
GSS CTRP2 0.807 2.4603 0.8056 34.8969
HSC-39 GDSC1; GDSC2 0.917 1.5649 0.9168 23.3002
NCC-StC-K140 CTRP2 1.2526 3.3834 1.2389 31.9694
SNU-16 GDSC1; GDSC2; CTRP2; CCLE 1.3333 2.4259 1.3333 31.386
ECC10 GDSC2; CTRP2 1.5237 3.821 1.4964 28.3235
HGC-27 GDSC2; CTRP2; CCLE 1.8647 3.8683 1.8463 26.1653
HuG1-N CTRP2 2.0778 4.9752 1.9535 26.8477
SNU-668 CTRP2 2.0874 4.6785 2.0079 26.6306
Fu97 GDSC2; CTRP2; CCLE 2.2311 3.5995 2.2284 25.4135
RERF-GC-1B GDSC2; CCLE 2.2806 4.325 1.8129 9.816
AZ-521 CCLE 2.2873 4.2276 1.7241 8.9185
NUGC-4 GDSC2; CTRP2; CCLE 2.2905 10.0803 0.4224 29.355
SNU-1 GDSC1; GDSC2; CTRP2; CCLE 2.3 4.0552 2.2854 23.4347
SNU-719 CTRP2 2.346 5.5667 2.1279 25.3884
BGC-823 CCLE 2.5026 4.5305 1.7889 7.9146
KE-39 CTRP2; CCLE 2.9171 5.4229 2.7789 21.3084
SNU-216 CTRP2 3.0005 4.4348 2.9883 20.3197
TMK-1 GDSC2 3.0228 5.2994 1.8692 6.4463
GSU CTRP2 3.0319 3.6347 3.0319 20.0694
MKN28 GDSC2 3.0939 5.1242 2.2243 5.7315
MKN1 GDSC2; CTRP2 3.1784 5.5781 3.0305 18.3794
OCUM-1 GDSC2; CCLE 3.195 6.3448 1.7035 7.9654
NUGC-3 GDSC2; CTRP2; CCLE 3.1973 4.5103 3.1872 17.8155
KATO III GDSC2 3.2716 5.4254 2.2279 5.3058
NCI-N87 GDSC1; GDSC2; CTRP2; CCLE 3.3476 4.8512 3.3215 16.9272
MKN74 CTRP2; CCLE 3.395 5.2918 3.3182 17.9122
RF-48 GDSC1; GDSC2 3.4425 6.0393 2.0624 5.7229
23132/87 GDSC2; CTRP2 3.4468 4.159 3.4466 16.2262
AGS GDSC2; CTRP2 3.4848 5.441 3.3896 16.2931
GCIY GDSC1; GDSC2; CCLE 3.6244 5.924 2.2636 4.4034
ECC12 GDSC2; CTRP2 3.6518 5.2107 3.6048 15.0942
SNU-601 CTRP2 3.6806 5.1613 3.6413 15.8807
LMSU CTRP2 3.8618 5.8955 3.7014 15.0983
SH-10-TC CTRP2; CCLE 3.8872 5.2003 3.8557 14.4775
MKN7 GDSC2; CTRP2; CCLE 4.1579 5.6954 3.8452 7.5674
SCH GDSC2 4.3545 12.1539 -0.503 15.857
TGBC11TKB GDSC2 4.4084 8.8101 1.4221 6.8985
SK-GT-2 GDSC2 4.5754 8.2693 1.7987 4.9107
SNG-M GDSC2; CTRP2; CCLE 2.5454 4.5083 2.5105 21.9661
SNU-685 CTRP2 3.2344 4.7879 3.1328 13.2946
SNU-1077 CTRP2 3.3738 4.6146 3.3639 17.8249
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KMH-2 GDSC2 1.4543 2.8203 1.3586 14.5497
FTC-238 CTRP2 2.1185 4.1703 2.091 26.2473
SW579 CTRP2; CCLE 2.1652 2.8447 2.1652 25.8439
TT GDSC2; CTRP2 2.2095 3.6206 2.2062 25.5598
K5 GDSC1; GDSC2 2.2388 3.8431 1.9656 9.2756
BHT-101 GDSC2; CTRP2 2.3282 3.5048 2.3272 23.2155
IHH-4 GDSC2 2.4118 4.2919 1.9626 8.7598
8305C GDSC2; CTRP2; CCLE 2.6248 4.33 2.6061 21.4184
B-CPAP GDSC2; CTRP2; CCLE 2.6435 4.3244 2.6257 21.299
8505C GDSC2; CTRP2; CCLE 2.7995 4.7615 2.7536 20.4137
CAL-62 GDSC2; CTRP2 3.041 4.3411 3.0337 18.7829
ML-1 [Human leukemia] GDSC2; CTRP2 3.2093 5.2612 3.1236 19.18
HTC-C3 GDSC2 3.2109 4.8297 2.4736 4.2772
CGTH-W-1 GDSC1; GDSC2; CTRP2 3.5294 4.2452 3.5291 16.756
ASH-3 GDSC2 3.9482 5.454 2.7217 1.7389
TT2609-C02 GDSC2; CTRP2; CCLE 3.9841 7.4125 3.3164 15.1745
WRO GDSC2 4.9199 9.8827 1.2588 6.7882
FTC-133 GDSC2; CTRP2 5.6629 9.6715 3.2239 6.5361
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-10B CTRP2 0.7513 2.5644 0.7487 35.272
JHU-011 GDSC2 1.5803 2.9666 1.4596 13.5243
DOK GDSC2 1.6469 4.0485 1.2544 14.2153
PCI-06A GDSC2 1.6741 3.6299 1.3428 13.742
Hs 840.T CCLE 1.8095 5.4547 0.6797 15.8598
KOSC-2 GDSC2 1.8342 4.2353 1.2619 13.5779
BB30-HNC GDSC1; GDSC2 1.9023 3.3457 1.6925 11.0437
BICR 18 CTRP2 1.91 3.9634 1.8469 22.6013
PCI-15A GDSC2 1.9627 3.4818 1.7076 10.7301
Detroit 562 GDSC2; CTRP2; CCLE 2.0199 4.7676 1.9236 25.444
SNU-1214 CTRP2 2.0321 4.3367 1.9873 26.8812
HO-1-N-1 GDSC2 2.0521 4.2064 1.6239 11.343
PE/CA-PJ49 CTRP2 2.1831 3.6917 2.1782 25.741
YD-8 CTRP2 2.1907 4.1582 2.1669 25.7537
KON GDSC2 2.228 3.9682 1.7827 9.353
HO-1-u-1 GDSC2 2.4114 4.5143 1.8636 11.8892
SCC-25 GDSC2; CTRP2; CCLE 2.4631 3.813 2.4595 23.8711
CAL-33 GDSC2; CTRP2 2.4904 4.4896 2.4545 22.3128
BHY GDSC2; CTRP2 2.5636 3.9462 2.5586 23.2063
BICR 31 GDSC2; CTRP2 2.5852 3.8343 2.5704 17.6062
HSC-3 GDSC2; CTRP2 2.6622 3.7067 2.6614 21.129
SAS GDSC2 2.7028 6.3437 1.2684 11.1848
SNU-1076 CTRP2 2.7077 4.3139 2.6926 22.28
SAT [Human HNSCC] GDSC2 2.9194 5.4567 1.903 7.6701
BICR 16 CTRP2 2.9335 5.0946 2.8537 20.9964
BICR 10 GDSC2 2.9478 5.3094 1.8015 5.95
Ca9-22 GDSC2 2.9546 4.998 2.1611 6.3692
PCI-04B GDSC2 2.983 5.7994 1.5861 6.9186
SNU-1041 CTRP2 2.9947 5.5744 2.8318 20.8787
SNU-46 CTRP2 2.9965 4.5259 2.9793 20.3633
BICR 22 GDSC2; CTRP2 3.0697 4.2319 3.045 13.2397
OSC-19 GDSC2 3.0745 5.2953 1.9138 6.0557
SNU-899 CTRP2 3.107 4.4152 3.0985 19.598
JHU-029 GDSC2 3.1419 5.1197 2.0559 5.0687
SNU-1066 CTRP2 3.1479 5.1708 3.0719 19.5553
BB49-HNC GDSC1; GDSC2 3.2059 7.8389 -0.8028 5.7523
NCI-H3118 GDSC2 3.2292 5.4045 2.2024 5.5216
BICR 6 CTRP2 3.2395 5.0232 3.1898 18.8544
OSC-20 GDSC2 3.262 5.1176 2.3736 4.6355
FaDu GDSC2; CTRP2; CCLE 3.2843 4.6556 3.2695 17.2866
CAL-27 GDSC2; CTRP2; CCLE 3.2994 5.3722 3.2019 17.4585
JHU-022 GDSC2 3.3647 6.0189 2.0089 6.1423
LB771-HNC GDSC1; GDSC2 3.3854 5.1741 2.4482 4.0123
SKN-3 GDSC2 3.4037 6.9377 1.5818 8.0836
PE/CA-PJ41 (clone D2) CTRP2 3.4234 5.104 3.3753 17.6242
PE/CA-PJ34 (clone C12) CTRP2 3.4765 5.1886 3.4208 17.2966
SCC-4 GDSC2 3.5075 6.7089 1.7805 6.9237
SCC-9 GDSC2; CTRP2; CCLE 3.547 5.2928 3.4812 15.8091
PE/CA-PJ15 GDSC2; CTRP2 3.6424 5.316 3.58 16.2145
BICR 78 GDSC2 3.8229 6.8258 1.968 5.4157
SCC-15 GDSC1; GDSC2 3.8795 6.2197 2.3073 3.7295
HSC-2 GDSC2; CTRP2; CCLE 3.9117 5.7877 3.7816 13.7432
HSC-4 GDSC2; CTRP2 3.9317 4.9616 3.9215 13.2288
PCI-30 GDSC2 4.1632 6.6352 2.3031 4.2382
UPCI-SCC-090 GDSC2 5.2644 11.8155 0.5647 9.279
BICR 56 CTRP2 5.3736 5.9328 5.3395 4.5865
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BFTC-905 GDSC2; CTRP2 1.9621 3.6037 1.9558 25.5189
253J CTRP2 2.2905 3.4547 2.2897 25.0117
RT-112 GDSC2; CTRP2; CCLE 2.3277 4.071 2.3131 23.2614
U-BLC1 CTRP2 2.3313 3.9603 2.3215 24.77
UM-UC-1 CTRP2 2.3321 4.3424 2.301 24.8364
JMSU-1 CTRP2; CCLE 2.4196 3.8688 2.4142 24.167
VM-CUB-1 CTRP2 2.5251 4.6699 2.4734 23.6206
5637 GDSC2; CTRP2; CCLE 2.6068 4.3233 2.5878 21.5319
253J-BV CTRP2 2.9359 3.8889 2.9353 20.7112
SCaBER CTRP2; CCLE 2.9502 4.8637 2.9017 20.7778
TCCSUP GDSC2; CTRP2; CCLE 3.0609 5.0099 3.0015 18.8243
RT-4 GDSC2; CTRP2; CCLE 3.0922 5.3531 2.9816 18.7949
SW1710 GDSC2; CTRP2 3.2365 4.9674 3.1932 17.6761
CAL-29 GDSC2; CTRP2 3.3985 4.8804 3.3723 16.6097
639V GDSC2; CTRP2; CCLE 3.4286 4.2596 3.4279 16.3414
647V GDSC2; CTRP2 3.4849 4.389 3.4832 15.9928
BC-3C CTRP2 3.5497 5.3254 3.4792 16.86
KU-19-19 GDSC2; CTRP2 3.5574 5.6156 3.4342 15.932
HT-1376 GDSC2; CTRP2; CCLE 3.561 5.9156 3.3682 16.1414
SW780 GDSC2; CCLE 3.6249 5.4098 2.5184 3.2036
UM-UC-3 GDSC2; CTRP2; CCLE 3.7759 5.6162 3.6711 15.4733
KMBC-2 CTRP2; CCLE 3.8469 5.6692 3.7373 15.0171
J82 GDSC2; CTRP2; CCLE 3.9509 6.0038 3.7707 13.6665
HT-1197 GDSC2; CTRP2; CCLE 3.972 5.5211 3.901 13.1721
T24 GDSC2; CTRP2; CCLE 4.427 7.474 3.7554 13.2799
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TC-YIK GDSC1; GDSC2 0.9611 2.8549 0.8563 18.1743
PA-1 GDSC2 1.7411 4.2219 1.2885 13.7703
NT2-D1 GDSC1; GDSC2 1.949 4.1346 1.5436 15.4622
JAR GDSC1; GDSC2 1.9779 3.1878 1.8281 10.0507
CAL-39 GDSC2 1.9967 4.8592 1.2878 12.999
JEG-3 GDSC2 2.3355 3.8938 1.9251 8.1984
KGN GDSC1; GDSC2 2.3717 6.5214 0.8747 17.7308
ACC-OV7 GDSC2 2.4507 4.363 1.82 8.3957
BPH-1 GDSC2 2.4669 4.8801 1.7514 9.5583
SW954 GDSC1; GDSC2 2.503 3.6779 2.1918 6.1554
Ca Ski GDSC2 2.8718 5.1898 1.9907 7.3765
OMC-1 [Human cervical carcinoma] GDSC1; GDSC2 2.8836 4.2965 2.2524 4.6197
NEC8 GDSC1; GDSC2 2.9255 4.8594 2.2021 6.2499
PWR-1E GDSC2 2.9784 5.0046 2.1795 6.2235
PEO1 GDSC2 3.0683 4.7829 2.3707 5.1024
MS751 GDSC2 3.0698 6.5282 1.5041 9.195
OVCA433 GDSC2 3.0919 5.4727 1.8394 6.4391
HEY GDSC2 3.1254 5.1827 2.2231 5.6627
OV17R GDSC2 3.185 5.4571 1.9221 5.7305
JHOS-3 GDSC2 3.2497 4.5772 2.4085 2.7978
NCC-IT GDSC1; GDSC2 3.3378 5.4959 2.2482 6.5187
HeLa GDSC2; CTRP2 3.4065 5.0318 3.3658 16.606
SiSo GDSC2 3.4567 7.124 1.532 8.2061
DoTc2 4510 GDSC2 3.4801 5.8362 2.1941 5.0205
C-33 A GDSC2 3.4851 6.3519 1.9407 6.2114
OVCA420 GDSC2 3.5152 5.0323 2.622 3.7781
UWB1.289 GDSC2 3.7186 5.6215 2.2288 2.8591
OVMIU GDSC2 3.8473 7.9872 1.4114 7.9802
C-4-I GDSC2 3.8959 7.7554 1.5635 7.1744
SKN GDSC2 3.9013 6.5109 2.1807 4.2792
SW962 GDSC1; GDSC2 3.9539 6.357 2.0343 3.4836
SW756 GDSC2 3.9891 6.5862 2.2068 4.0054
HEC-1 GDSC2 4.3005 6.5823 2.4172 2.5721
DSH1 GDSC1; GDSC2 4.3261 8.2612 1.6309 6.0823
HT-3 GDSC2 4.4761 8.8561 1.4477 6.6653
SiHa GDSC2 4.6843 8.9501 1.5463 5.8751
LB831-BLC GDSC1; GDSC2 4.7027 12.2182 -0.0345 12.8177
SKG-IIIa GDSC2 5.5394 11.8288 0.7443 8.0696
ME-180 GDSC2 7.9858 19.858 -1.4574 12.8711
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Crizotinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ceritinib DMB920Z Major Decreased metabolism of Crizotinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [14]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Crizotinib caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [15]
PF-06463922 DMKM7EW Moderate Increased metabolism of Crizotinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [16]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Crizotinib and Osimertinib. Lung cancer [2C25] [17]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Crizotinib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [18]
Capmatinib DMYCXKL Moderate Decreased metabolism of Crizotinib caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [19]
Selpercatinib DMZR15V Major Decreased metabolism of Crizotinib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [20]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Crizotinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Crizotinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [14]
Metreleptin DM1NOEK Moderate Increased metabolism of Crizotinib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [16]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Crizotinib and Ivosidenib. Acute myeloid leukaemia [2A60] [21]
Arn-509 DMT81LZ Major Increased metabolism of Crizotinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Crizotinib and Gilteritinib. Acute myeloid leukaemia [2A60] [17]
Oliceridine DM6MDCF Major Decreased metabolism of Crizotinib caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [22]
Ivabradine DM0L594 Major Decreased metabolism of Crizotinib caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [23]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Crizotinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [24]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Crizotinib and Levalbuterol. Asthma [CA23] [25]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Crizotinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [26]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Crizotinib and Eribulin. Breast cancer [2C60-2C6Y] [17]
Talazoparib DM1KS78 Moderate Decreased clearance of Crizotinib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [27]
HKI-272 DM6QOVN Major Decreased metabolism of Crizotinib caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
LY2835219 DM93VBZ Moderate Decreased metabolism of Crizotinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Tucatinib DMBESUA Major Decreased metabolism of Crizotinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [14]
Palbociclib DMD7L94 Moderate Decreased metabolism of Crizotinib caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Macitentan DMP79A1 Moderate Decreased metabolism of Crizotinib caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [30]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Crizotinib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [17]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Crizotinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [31]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Crizotinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [25]
Intedanib DMSTA36 Moderate Decreased clearance of Crizotinib due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [32]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Crizotinib and Osilodrostat. Cushing syndrome [5A70] [17]
MK-8228 DMOB58Q Moderate Decreased metabolism of Crizotinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [17]
OPC-34712 DMHG57U Major Decreased metabolism of Crizotinib caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [33]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Crizotinib and Deutetrabenazine. Dystonic disorder [8A02] [17]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Crizotinib and Ingrezza. Dystonic disorder [8A02] [17]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Crizotinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Cannabidiol DM0659E Minor Decreased metabolism of Crizotinib caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [20]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Crizotinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [34]
Tazemetostat DMWP1BH Major Decreased metabolism of Crizotinib caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [35]
Mirabegron DMS1GYT Minor Decreased metabolism of Crizotinib caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [36]
Ripretinib DM958QB Moderate Decreased metabolism of Crizotinib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [14]
Avapritinib DMK2GZX Major Decreased metabolism of Crizotinib caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [20]
Boceprevir DMBSHMF Major Decreased metabolism of Crizotinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [14]
MK-1439 DM215WE Minor Decreased metabolism of Crizotinib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Crizotinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [17]
Cobicistat DM6L4H2 Major Decreased metabolism of Crizotinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Dolutegravir DMCZGRE Minor Decreased metabolism of Crizotinib caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Crizotinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [39]
Aliskiren DM1BV7W Moderate Decreased clearance of Crizotinib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [39]
Lesinurad DMUR64T Moderate Increased metabolism of Crizotinib caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [16]
Berotralstat DMWA2DZ Major Decreased clearance of Crizotinib due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [40]
Suvorexant DM0E6S3 Major Decreased metabolism of Crizotinib caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [41]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Crizotinib caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [42]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Crizotinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [20]
Naloxegol DML0B41 Major Decreased metabolism of Crizotinib caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [20]
Pemigatinib DM819JF Major Decreased metabolism of Crizotinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [20]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Crizotinib caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [16]
Artesunate DMR27C8 Moderate Decreased clearance of Crizotinib due to the transporter inhibition by Artesunate. Malaria [1F40-1F45] [14]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Crizotinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [43]
Idelalisib DM602WT Major Decreased metabolism of Crizotinib caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [14]
GDC-0199 DMH0QKA Major Decreased metabolism of Crizotinib caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [14]
IPI-145 DMWA24P Moderate Decreased metabolism of Crizotinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [44]
Acalabrutinib DM7GCVW Major Decreased metabolism of Crizotinib caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [45]
Ibrutinib DMHZCPO Major Decreased metabolism of Crizotinib caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [46]
Ponatinib DMYGJQO Moderate Decreased metabolism of Crizotinib caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [47]
Arry-162 DM1P6FR Moderate Decreased clearance of Crizotinib due to the transporter inhibition by Arry-162. Melanoma [2C30] [14]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Crizotinib and Vemurafenib. Melanoma [2C30] [39]
Selumetinib DMC7W6R Major Decreased metabolism of Crizotinib caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [48]
LGX818 DMNQXV8 Major Decreased metabolism of Crizotinib caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [49]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Crizotinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [20]
Ubrogepant DM749I3 Moderate Decreased metabolism of Crizotinib caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [50]
Rimegepant DMHOAUG Moderate Decreased metabolism of Crizotinib caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [51]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Crizotinib and Siponimod. Multiple sclerosis [8A40] [14]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Crizotinib and Fingolimod. Multiple sclerosis [8A40] [39]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Crizotinib and Ozanimod. Multiple sclerosis [8A40] [17]
Deflazacort DMV0RNS Major Decreased metabolism of Crizotinib caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [20]
Fedratinib DM4ZBK6 Minor Decreased metabolism of Crizotinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [17]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Crizotinib caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [20]
Entrectinib DMMPTLH Major Decreased metabolism of Crizotinib caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [14]
S-297995 DM26IH8 Moderate Decreased metabolism of Crizotinib caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [20]
Olaparib DM8QB1D Major Decreased metabolism of Crizotinib caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [14]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Crizotinib and Rucaparib. Ovarian cancer [2C73] [17]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Crizotinib and Triclabendazole. Parasitic worm infestation [1F90] [17]
Istradefylline DM20VSK Moderate Decreased metabolism of Crizotinib caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [17]
Abametapir DM2RX0I Moderate Decreased metabolism of Crizotinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [52]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Crizotinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [53]
Lefamulin DME6G97 Major Decreased metabolism of Crizotinib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [54]
Enzalutamide DMGL19D Major Increased metabolism of Crizotinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [14]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Crizotinib and Relugolix. Prostate cancer [2C82] [55]
Darolutamide DMV7YFT Minor Decreased metabolism of Crizotinib caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [56]
Riociguat DMXBLMP Moderate Decreased metabolism of Crizotinib caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [14]
Upadacitinib DM32B5U Moderate Decreased metabolism of Crizotinib caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [57]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Crizotinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [58]
LDE225 DMM9F25 Major Decreased metabolism of Crizotinib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [59]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Crizotinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [20]
Larotrectinib DM26CQR Moderate Decreased clearance of Crizotinib due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [14]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Crizotinib and LEE011. Solid tumour/cancer [2A00-2F9Z] [17]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Crizotinib and Pitolisant. Somnolence [MG42] [17]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Crizotinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [60]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Crizotinib and Lenvatinib. Thyroid cancer [2D10] [17]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Crizotinib and Cabozantinib. Thyroid cancer [2D10] [17]
Elagolix DMB2C0E Moderate Increased metabolism of Crizotinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [16]
Fluticasone DMGCSVF Moderate Decreased metabolism of Crizotinib caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [14]
Betrixaban DM2C4RF Moderate Decreased clearance of Crizotinib due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [61]
⏷ Show the Full List of 95 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Ammonia E00007 222 Alkalizing agent
Calcium hydrogenphosphate E00294 24441 Diluent
Eisenoxyd E00585 56841934 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Crizotinib 200 mg capsule 200 mg Oral Capsule Oral
Crizotinib 250 mg capsule 250 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903).
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
6 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
7 Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94.
8 Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
9 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
10 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
11 Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25.
12 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
13 Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
14 Cerner Multum, Inc. "Australian Product Information.".
15 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
16 Cerner Multum, Inc. "Canadian Product Information.".
17 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
18 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
19 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
20 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
22 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
23 Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
24 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
25 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
26 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
27 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
28 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
29 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
30 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
31 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
32 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
33 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
34 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
35 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
36 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
37 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
38 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
39 Canadian Pharmacists Association.
40 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
41 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
42 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
43 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
44 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
45 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
46 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
47 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
48 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
49 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
50 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
51 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
52 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
53 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
54 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
55 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
56 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
57 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
58 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
59 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
60 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
61 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.